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Abstract 
 
Several new qPCR assays have been developed in single and multiplex modes for quantifying DNA 
in forensic samples.  These assays, listed below, were developed to improve the accuracy and precision of 
DNA quantifications, as well as to provide tools to increase the efficiency and throughput of the analysis of 
complex forensic samples: 
(i) a duplex assay that quantifies simultaneously the human nuclear and mitochondrial genomes.  
This assay was developed to quantify DNA in the degraded samples that are often encountered in missing 
person’s cases.  It has been optimized and validated for forensic casework. 
(ii) a triplex assay that quantifies two human nuclear target sequences, one target that is ~170-190 
basepairs (bp) in length and the other 67 bp in length, and that also includes an internal positive control (IPC) 
assay.  By comparing quantifications from the two differently sized nuclear target sequences, the assay 
effectively estimates the extent of DNA degradation in a sample.  Moreover, the IPC portion of the assay 
provides a means for detecting for the presence of co-extracted PCR inhibitors.  In addition to the triplex 
assay, a duplex assay, which quantifies the long nuclear target sequence and detects the IPC, has also been 
developed. 
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(iii) several singleplex assays to quantify specifically the human Y-chromosome. 
All assays (i-iii) were developed utilizing 5’-hydrolysis (“TaqMan®”) detection chemistries for data 
collection on the ABI 7000 instrument.  Most features should be portable to other real-time qPCR 
instruments capable of multiplex detection and so should be of general utility to the forensic community.  
Two of the assays ((i) and (ii)) have been described in manuscripts accepted for publication.  We have also 
initialized formalized training in the application of qPCR to forensic samples through a course that is offered 
through the California Criminalistics Institute.  This course includes discussion of the theory of qPCR, as 
well as hands-on laboratory and data analysis experiences with real-time qPCR assays developed here and 
elsewhere.  
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Executive Summary: 
 
The quantitation of DNA plays a central role in all areas and applications of forensic DNA analysis.  
The careful evaluation of the quantity of DNA extracted from biological samples is an imperative for DNA 
typing via the Polymerase Chain Reaction (PCR).  For example, very discrete windows of input DNA 
concentration are allowed for balanced amplification of the 13 CODIS STR loci with the commercial kits 
that are commonly used for forensic casework and databank genotyping.  Stochastic effects peculiar to the 
PCR take over above and below a narrow range of DNA optima for the typing assays.  In addition, in the 
forensic arena, quantitation is often crucial as samples may be limited.  Surprisingly, the DNA quantitation 
methods commonly employed in forensics are often less than accurate, are time consuming, and require the 
consumption of a substantial percentage of what may be a precious sample.  In general, forensic analysts 
have learned to work with less than ideal quantitation methods, which are thought by many to be “good 
enough.” 
In order to improve the accuracy and precision of DNA quantifications, as well as to provide tools to 
increase the efficiency and throughput of the analysis of complex forensic samples, we have developed 
several new quantitation assays based on real-time quantitative PCR (qPCR) methods.  These assays include: 
(i) a duplex qPCR assay that quantifies simultaneously the human nuclear and mitochondrial  
genomes;  
(ii) a triplex assay for assessing the quantity and quality (DNA fragmentation and presence of PCR  
inhibitors) of human nuclear DNA;  
(iii) several singleplex assays to quantify human male (Y-chromosomal) DNA. 
The nuclear-mitochondrial duplex qPCR assay (i) was developed primarily for the type of degraded 
and compromised samples that are commonly encountered in missing persons’ evidence.  For such evidence, 
the extracted DNA can be so degraded or so limited in quantity that attempts to genotype using the standard 
autosomal STR analysis methods are often unsuccessful.  Under these circumstances, a common approach is 
to turn to the large number of mitochondrial copies (initially present in 100s of copies per cell) that might 
remain intact and available for analysis, for example by DNA sequencing.  For such samples, accurate and 
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sensitive assessments of the quantities of both the nuclear and mitochondrial genomes are very valuable in 
guiding the DNA analyst to the most effective and efficient genotyping approach, and it is for this purpose 
that the nuclear-mitochondrial duplex qPCR assay was developed and validated.  For this assay, the nuclear 
portion utilized amplification of a ~170-190 bp target sequence that spans the repeat region of the TH01 STR 
locus, and the mitochondrial portion of the assay utilized amplification of a 69 bp target sequence in the ND1 
region.  Validation studies included evaluations of species specificity, sensitivity, precision, and 
reproducibility, as well as applications to various casework-type samples.  In addition, a series of DNase-
degraded samples were quantified using three methods: the nuclear-mitochondrial duplex qPCR assay; a 
qPCR assay that uses a much shorter (62 bp) target sequence; and slot blot hybridization.  For non-degraded 
and moderately degraded samples in the series, all three methods were suitably accurate for estimating the 
quantity of nuclear DNA template to achieve successful STR amplification and genotyping.  However, for 
highly degraded samples, the duplex qPCR assay provided better estimates of nuclear template than did 
either the 62 bp qPCR assay, which overestimated the quantity of STR-sized DNA fragments, or slot blot 
hybridization, which underestimated the quantity of nuclear DNA.  The nuclear-mitochondrial duplex qPCR 
assay has been validated for casework in the California DOJ Missing Persons DNA Program and is 
anticipated to go “on-line” by May 2005. 
In the course of developing the nuclear-mitochondrial duplex qPCR assay, it became clear that an 
assay that could simultaneously assess DNA quantity and quality (i.e., degree of fragmentation, presence of 
inhibitors) would be very useful for highly compromised samples.  To this end, we developed a multiplex 
quantitative PCR assay (ii) to amplify target sequences of different length, which allows for the assessment 
of DNA degradation in samples of forensic interest. The targets were chosen to provide quantification and 
fragment length information relevant to the STR amplification targets commonly used for forensic 
genotyping. The longer target (nuTH01, 170-190 bp) spans the TH01 STR locus. Although not one of the 
longest loci used for STR genotyping, it was chosen as a good compromise given the target length limitations 
on qPCR efficiency with TaqMan® detection. The shorter target (nuCSF, 67 bp) was designed in the 
upstream flanking region of the CSF1PO STR locus. In addition to these human nuclear targets, the assay 
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includes an internal PCR control (IPC) target sequence to allow for an assessment of PCR inhibition. The 
assay was rigorously tested on samples with varying amounts of degradation, and the ratio of 
nuCSF:nuTH01 quantifications was shown to provide a good estimation of the degree of degradation present 
in a sample. This estimate, along with the internal control for PCR inhibition, provides a valuable tool for 
post-extraction sample assessment.  In addition, this triplex assay has been evaluated for species specificity, 
precision, and sensitivity to PCR inhibition. 
The development of a qPCR assay specific for the human Y-chromosome was motivated primarily 
by its potential utility for the analysis of sexual assault casework samples.  Such an assay would allow the 
analyst to differentiate those samples that contain sufficient male DNA for genotyping from those that 
contain so little male DNA that further analyses, at least by the STR methods currently in common use, 
would be uninformative.  Moreover, the combined quantitation information from a Y-specific qPCR assay 
and an autosome-specific qPCR assay could provide an estimate of the relative amounts of human male and 
female DNA in an extract.  This information could then be used to differentiate those samples that would 
benefit from “standard” autosomal STR genotyping approaches (i.e., those samples with 
maleDNA:femaleDNA ratios greater than ~1:10) from those samples that would be analyzed more 
productively using Y-specific amplification methods (e.g., Y-STRs).  To this end, we developed several Y-
specific qPCR assays.  These assays have been evaluated for their specificity to the Y-chromosome, as well 
as for sensitivity and precision.  The development of an autosomal-Y duplex qPCR assay is currently 
ongoing.  
We have presented our qPCR results at several forensic venues (the 4
th and 5
th Annual DNA 
Grantees’ Meetings in Washington (DC), the 14
th Promega International Symposium on Human 
Identification in Phoenix (AZ)), and two manuscripts have been accepted for publication.  In addition, we 
offer training in forensic aspects of qPCR through a California Criminalistics Institute course.  This course 
includes a lecture component, as well as hands-on laboratory and computer data analysis experience with 
various forensic qPCR assays. 
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Introduction 
 
The quantitation of DNA plays a central role in all areas and applications of forensic DNA analysis.  
The careful evaluation of the quantity of DNA extracted from biological samples is an imperative for DNA 
typing via PCR.  For example, very discrete windows of input DNA concentration are allowed for balanced 
amplification of the 13 CODIS STR loci with the commercial kits that are commonly used for forensic 
casework and databank genotyping.  Stochastic effects peculiar to the PCR take over above and below a 
narrow range of DNA optima for the typing assays.  In addition, in the forensic arena, quantitation is often 
crucial as samples may be limited.  Surprisingly, the DNA quantitation methods commonly employed in 
forensics are often less than accurate, are time consuming, and require the consumption of a substantial 
percentage of what may be a precious sample.  In general, forensic analysts have learned to work with less 
than ideal quantitation methods, which are thought by many to be “good enough.” 
     Yield gel procedures using ethidium bromide fluorescence provide information about the quantity 
and quality (in terms of overall molecular weight).  This procedure, however, may require the consumption 
of a significant amount of sample, due to its poor sensitivity, and does not result in a quantitation that is 
specific to human DNA.  In addition, quantitation results obtained by this method are only relatively 
accurate.  Other quantitation approaches based on fluorescent detection, such as those using PicoGreen
TM (1) 
or SYBR
TM Green (2), also suffer from lack of human specificity since they are intercalating dyes that detect 
for the presence of any sources of double-stranded DNA.   QuantiBlot
TM, another commonly employed 
technique in the forensic laboratory (3), is more sensitive than gel electrophoresis and utilizes a human 
(primate) specific probe.   The QuantiBlot
TM method is, however, labor intensive to perform and suffers from 
a lack of accuracy.  More recently, an ingenious method, the AluQuant™ Human DNA Quantitation System 
(4), has been developed for human-specific quantitation of forensic samples without requiring 
immobilization of the sample as QuantiBlot
TM does.  This procedure employs a series of enzymatic reactions 
to produce a luminescent signal proportional to the quantity of human DNA present. 
The intensification of large scale suspect-less casework programs and, more recently, the 
implementation of teams devoted to the identification of human remains by means of DNA typing 
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suggest that DNA quantitation, which has been done so far by labor-intensive techniques and likely 
not susceptible by their very nature to great productivity gains, would benefit from fresh 
approaches.  Clearly, the efficiency of forensic DNA analysis would benefit from any new mode of 
quantitation that would be more accurate, more susceptible to automation, and more sensitive for 
estimating quantities in low-copy number samples (Table 1). 
TABLE 1 - A comparison of forensic DNA quantification methods. 
Method 
 
Human 
Specific/ 
Sample 
Investment 
Sensitivity 
(pg*)/Accuracy 
Instrumentation 
Requirements 
Time to 
Completion 
(hrs) 
Samples per 
Quantitation 
Event 
Personnel 
Time 
Required 
Potential 
Automation/Multiplex 
Ethidium 
Bromide  no/high 1000/low  low  2  24  high  no/no 
PicoGreen
TM no/low 50/high  high  1  86  low  yes/no 
QuantiBlot
TM yes/low 25-50/low  low  4-6  32  high  no/no 
AluQuant
TM yes/low 100/high  medium  4  90  low  yes/no 
qPCR yes/low ~30/high  highest  2  84  lowest  yes  /yes 
* assuming ~3.3 pg per haploid human nuclear genome 
 
Objectives 
  In our NIJ grant proposal, we proposed to use real-time quantitative PCR (qPCR), a method 
commonly employed for a variety of molecular diagnostic and biotechnology procedures, for the 
quantification of DNA in forensic samples.  In particular, we were interested in developing qPCR assays to 
quantify the human nuclear genome, the human mitochondrial genome, and the human Y-chromosome, and, 
as appropriate, to multiplex these assays in order to quantify more than one genome (or chromosome) in a 
single reaction.  For example, we anticipated that a human-specific nuclear/mitochondrial duplex assay 
would be an especially useful tool for quantifying DNA in the highly compromised samples that are 
commonly encountered in missing person’s cases.  Such an assay would allow the analyst to quickly 
differentiate those samples that contain enough nuclear DNA for successful STR genotyping from samples 
that contain such small quantities of DNA that they would only benefit from mitochondrial haplotyping or 
from those that are essentially bereft of any human DNA.  In addition, we expected that a human-specific 
nuclear/Y-chromosome duplex assay would be especially useful for increasing the throughput of analysis for 
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the large number of suspect-less sexual-assault evidence kits that are being processed, allowing the analyst to 
efficiently identify samples that contain sufficient quantities of male DNA for genotyping.  Using such newly 
developed tools, we anticipated that increases in the efficiency of DNA analysis would lead to improved 
genotyping results at lower costs.  As described in our proposal, for each assay, our objectives were to 
develop, optimize, and validate according to SWGDAM guidelines, and also to make the assays available to 
the forensic community through presentations, publications, and training. 
 
Progress Toward Meeting Objectives 
  As we will describe in the remainder of this final report, we were successful in meeting the majority 
of our objectives.  We have developed a number of qPCR assays that are useful for quantifying DNA in 
forensic samples: a nuclear/mitochondrial duplex assay and several Y-specific qPCR assays.  The 
nuclear/mitochondrial duplex assay has undergone extensive on-site validation, a standard operating protocol 
has been written for this assay, and it is expected to go “on-line” in the California DOJ Missing Persons 
DNA Program (MPDP) by May 2005.  Much of the developmental work surrounding these assays has been 
presented at forensic meetings as oral or poster presentations (5-8), and two manuscripts have been accepted 
for publication (9-10).  In the area of training, we have offered and will continue to offer, as demand 
requires, a one-week course that includes theory, hands-on laboratory, and computer instruction in forensic 
qPCR.  The first offering of this course, “Advanced DNA Extraction and Quantification with Real Time 
qPCR” (R220), was offered through the California Criminalistics Institute and was attended by a total of 12 
forensic DNA analysts, seven from the California DOJ Missing Persons DNA Program and five from non-
DOJ agencies in California (the LA County Sheriff Dept, the Fresno County Sheriff Dept, the Orange 
County Sherriff Dept, the San Diego Police Dept, and the San Diego County Sheriff Dept). 
Throughout the development and validation of the aforementioned qPCR assays, we gained 
experience in collecting data on various types of samples, and we began to identify critical issues for 
obtaining accurate qPCR quantifications.  In particular, as part of the validation of the duplex 
nuclear/mitochondrial assay, experiments with samples containing highly degraded DNA indicated that the 
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length of the qPCR-amplified target sequence was one of the most important issues for obtaining accurate 
quantifications for STR genotyping applications.  This observation motivated us to develop a duplex qPCR 
assay that could simultaneously amplify and quantify two nuclear target sequences of different length, 
allowing for an assessment of the extent of DNA degradation in samples.  This duplex “degradation qPCR 
assay” was subsequently augmented to include an Internal PCR Control (IPC) amplification.  The resulting 
triplex qPCR assay, which is described in some detail later in this report and in a submitted manuscript (10), 
provides an estimation of both quantity and quality (degree of degradation and presence of co-extracted PCR 
inhibitors) of the extracted DNA.  It should be very useful as a diagnostic tool for analyzing DNA in highly 
compromised casework samples. 
 
qPCR Fundamentals 
 
  The quantification of DNA via the real-time detection of PCR-amplified target sequences was first 
described by Higuch et al. in a 1993 report (11) that outlined the basic principles of what the authors called 
“kinetic PCR” but what is now more commonly referred to as qPCR.  Although these early experiments used 
home-built instrumentation, the utility of qPCR for quantifying polynucleic acids was quickly recognized 
and a commercial instrument was on the market by 1996 (the Perkin-Elmer ABI 7700 Sequence Detection 
System).  The increasing use and acceptance of qPCR in biomedical research and in molecular diagnostics is 
evident from both the rapid growth in peer-reviewed papers that use the method (8 publications in 1998, 
>500 in 2002) (12) and the current availability of real-time qPCR instruments from a variety of vendors (e.g., 
ABI, Roche, BioRad, Stratagene, Corbett).  As mentioned in a recent review article (13), qPCR is “a 
technique whose time has come.” 
The quantification of DNA by qPCR relies on the detection of amplified product (“amplicon”) at 
each cycle of the PCR.  Detection of the PCR product is accomplished with the use of thermal cyclers that 
are capable of measuring real-time fluorescence changes due to amplicon production.  The result is an 
“amplification curve” (Figure 1) for each sample.  As indicated in this figure, the amplification curve can be 
separated into at least three phases: (i) the “lag” phase, during which the PCR is occurring efficiently 
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(exponential growth), but the amplicon-induced fluorescence is at or below the background level of 
detection; (ii) the “exponential” phase, during which the PCR is occurring efficiently and the signal is above 
background; and (iii) the “plateau” phase, which occurs during later cycles of the PCR, at which point 
amplification efficiencies are reduced by such factors as polymerase degradation, reactant consumption, and 
amplicon re-annealing (in competition with binding of the PCR primers). 
 
FIG. 1 - qPCR Amplification Curve.  R is the fluorescence signal at each cycle due to amplicon production.  
Locations of lag, exponential, and plateau phases of the curve are indicated.  The Ct (or CT) value for the 
curve is the cycle at which the amplification curve crosses the user-selected threshold. 
 
In qPCR, the accurate quantification of DNA relies on using data from the exponential phase of the 
amplification curve.  In particular, for each amplification curve, a “cycle threshold” (Ct or CT) is defined as 
the cycle number at which the curve crosses a fluorescence threshold that has been established for the assay 
(Figure 1).  This threshold is selected to be high enough to avoid background noise in the fluorescence 
signal, but low enough to remain in the exponential portion of the amplification curve, thereby avoiding 
confounding effects due to the lowered PCR efficiencies encountered in the plateau phase.  Qualitatively, a 
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low CT indicates the presence of more initial template DNA than does a higher CT, because the lower value 
indicates that fewer cycles are needed to produce sufficient amplicon for fluorescence detection.  (Ideally, for 
a qPCR assay operating at 100% efficiency, a single cycle delay in CT represents a 2-fold decrease in the 
initial quantity of template DNA in the sample.)  Quantitatively, the initial amount of template DNA in an 
unknown sample is determined from CT by use of a standard curve derived from qPCR data collected for a 
dilution series of a known DNA quantitation standard (Figure 2).  Due to the exponential nature of qPCR, a 
plot of the CT vs. the logarithm of the initial concentration in each standard dilution leads to a straight line for 
the standard curve.  The quantity of DNA in each unknown sample can then be deduced from its CT by 
interpolation from this line.  Fortunately, these post-run manipulations of the data (e.g., determination of CT 
for each sample, development of the standard curve, and interpolation to estimate DNA quantity) are semi-
automated features on all commercial qPCR systems. 
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(a) Amplification curves for a dilution series of standard, quantified DNA.  Quantities shown are in 
ng of genomic DNA.  Delta Rn is the normalized, baseline-corrected fluorescence signal for each 
sample. 
 
 
FIG. 2 - Development of a qPCR Standard Curve. (figure continued on following page) 
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(b) Standard curve based on data from (a).  Ct is the cycle threshold as determined from the 
amplification curve plot.  C0 is the known quantity of input template (in ng). 
 
FIG. 2 - Development of a qPCR Standard Curve.(continued) 
 
Although a wide variety of fluorescence-based detection chemistries have been developed for real-
time qPCR applications (14), many assays currently use (i) SYBR
TM Green or (ii) 5’-hydrolysis 
(“TaqMan
TM”) chemistry for amplicon detection.  These methods are briefly presented in Figure 3.  The 
SYBR
TM Green method, which relies on the large increase in fluorescence signal when the dye binds to 
double-stranded DNA (i.e., to the qPCR amplicon), is typically the simpler method to implement, but is 
limited to singleplex quantifications.  In addition, SYBR
TM Green will detect non-specific amplification 
products, for example, due to “primer dimers” or spurious cross-reactivity to non-target sequences.  
TaqMan
TM assays, which utilize a sequence-specific dye-labeled oligonucleotide (a “TaqMan
 TM probe”), are 
often more difficult to design and develop, but can be more specific than SYBR
TM Green-detected assays.  
More significantly, by using differently labeled TaqMan probes for different target sequences (e.g., FAM-
label for a nuclear target sequence and VIC-label for a mitochondrial target sequence), the TaqMan
TM 
approach allows for the possibility of multiplexing two or more different assays in a single tube (17). 
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(a) SYBR
TM Green detection (15).  Upon extension, the SYBR
TM Green reporter dye binds to the double-
stranded amplicon as it forms.  Upon binding, the emission intensity of the dye increases by many fold. 
 
 
 
 
(b) TaqMan
TM Detection (16).  The TaqMan
TM probe is complimentary to sequence of one amplicon strand 
between the forward and reverse primers.  Each probe is dual-labeled with a reporter dye (R, e.g., FAM) on 
the 5’ end and a fluorescence quencher (Q) on the 3’ end.  Upon extension, the 5’nuclease activity of Taq 
polymerase cleaves the TaqMan
TM probe so that for each cycle of PCR an additional fluorophore is released 
per amplicon. 
 
FIG. 3 - Selected real-time qPCR detection chemistries. 
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There are a number of experimental factors that influence the accuracy of qPCR quantifications.  
One of these is the presence of co-extracted PCR inhibitors, which can lead to underestimations of DNA 
quantities due to amplifications curves with delayed CT’s and shallow slopes.  If a sample is sufficiently 
inhibited, the result can be the complete absence of detectable PCR product (a null amplification).  Although 
the presence of PCR inhibition can sometimes be deduced from the shape of the amplification curve, another 
approach has been to spike the quantification assay with an Internal PCR Control (IPC) assay for detecting 
the presence of inhibitors.  (We will describe this approach in more detail later in this report as part of the 
discussion of our triplex degradation qPCR assay.)   
Another factor that must be considered when assessing the accuracy of qPCR is the extent of 
fragmentation of the extracted DNA.  DNA samples can be highly degraded due to environmental or 
microbial exposures.  For such samples, there will be a greater number of smaller than larger DNA 
fragments, a circumstance that is readily seen in the STR intensity profiles of degraded samples (e.g., off-
scale short Amelogenin alleles and undetected long CSF1PO STR alleles).  A qPCR assay based on the 
amplification of a single target sequence will necessarily quantify those DNA fragments that are as long or 
longer than the target sequence.  As a consequence, for highly degraded samples, the quantities of DNA 
measured by assays that measure short and long target sequences can differ significantly.  As we will discuss 
later in this report, for the purpose of STR genotyping, there are advantages to choosing a qPCR target 
sequence that measures relatively long (>150 bp) target sequences.   
One additional factor that influences the accuracy of the qPCR measurement is the accuracy of the 
quantitation of the “known” DNA that is being used to develop the standard curve.  The qPCR assay can be 
no more accurate than the calibration standard.  Although NIST is currently looking into the establishing a 
standard reference material for DNA quantifications, forensic labs often rely on the use of pre-quantified 
vendor-supplied DNA extracts that have been quantified by UV-vis spectroscopy. 
Advantages of qPCR 
 
qPCR has a number of features, summarized below, that make it particularly attractive for 
quantifying DNA in forensic samples: 
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(i) qPCR is based on the same principle (the polymerase chain reaction) as are the techniques 
commonly used for forensic genotyping (e.g., the PCR amplification of short tandem repeats in chromosomal 
DNA and of polymorphic regions in the mitochondrial genome).  Consequently, qPCR provides particularly 
relevant information about the quantity of “amplifiable” DNA in sample.  That is, the qPCR method is 
sensitive not only to the quantity of DNA, but also to the quality of DNA (e.g., degree of DNA degradation, 
amount of co-extracted PCR inhibitors). Techniques such as membrane hybridization (e.g., QuantiBlot
TM), 
solution hybridization (e.g., AluQuant
TM) and dye binding/intercalation (e.g., PicoGreen
TM) are not based on 
PCR and do not necessarily provide relevant quantifications of “amplifiable” DNA. 
(ii) qPCR assays can be designed to be very specific to the DNA target sequence of interest.   For 
example, primate-specific PCR primers can be used for quantifying nuclear DNA in forensic samples, and 
assays can be similarly designed to be highly specific for other forensically relevant chromosomes (e.g., to 
the Y-chromosome) or genomes (e.g., to the mitochondrial genome or to genomes of non-human organisms). 
(iii) qPCR assays can be designed to amplify, detect and quantify more than one 
genome/chromosome of interest in a single tube.  This ability to multiplex assays relies on the use of probes 
labeled with different fluorophores to detect different DNA target sequences (e.g., FAM for one target 
sequence, VIC for a different target sequence), as well as on the use of instruments capable of separately 
detecting the fluorescence emissions from the different probes.  Although multiplex assays are more 
challenging to develop than singleplex assays, they offer the advantages of providing the maximum amount 
of information while consuming a minimal amount of extract, analyst time and labor. 
(iv) Because of the exponential nature of PCR, qPCR assays have a very large dynamic range of 
detection.  Assays can be sensitive enough to detect down to just a few copies of the target sequence of 
interest, although the accuracy and precision of qPCR assays typically decrease when fewer than ~10 copies 
of target sequence are present for detection.  And, under most conditions, qPCR assays can accurately 
quantify tens of thousands of target sequences.  Consequently, qPCR dynamic detection ranges readily span 
the roughly three orders of magnitude (~30 pg - ~30 ng of nuclear DNA) needed for most forensic 
applications. 
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(v) Compared to most of the commonly used quantification methods (the non-human-specific 
PicoGreen
TM method being the exception), the experimental protocols for qPCR assays are straightforward, 
laborsaving, and amenable to automation.  Moreover, qPCR data analysis is largely automated. 
 
Cal-DOJ-Developed qPCR Assays 
 
  The remaining sections of this report describe selected aspects of the development and validation of 
the qPCR assays that comprised the bulk of work performed under the NIJ award.  In the first section (i), we 
describe a duplex qPCR assay capable of simultaneously quantifying human nuclear and mitochondrial 
DNA.  This assay, which was developed primarily for quantifying DNA in the type of highly compromised 
samples encountered in missing persons programs, was found to be particularly suited for quantifying highly 
degraded DNA for STR typing.  In the second section (ii), we describe a triplex qPCR assay that was 
developed to assess DNA quantity and quality in forensic samples.  In the third section (iii), several Y-
chromosome-specific qPCR assays are described, which will be used in a duplex autosomal-Y qPCR assay 
that is currently under development. 
 
(i) A Duplex Real-Time qPCR Assay for the Quantification of Human Nuclear and Mitochondrial 
DNA in Forensic Samples:  Implications for Quantifying DNA in Degraded Samples 
 
Introduction 
The need to increase throughput in forensic DNA genotyping has led to a growing interest in 
developing new DNA quantification methods that are more efficient than the slot blot hybridization method 
currently used in many forensic DNA labs (18).  The slot blot method, though it offers excellent specificity 
and good sensitivity (3,19), relies on a protocol that is time-consuming, labor-intensive, and not readily 
transferable to automation.  In response, there have been a number of recent publications that describe 
alternative approaches for quantifying DNA in forensic samples, including a liquid hybridization assay (4,20) 
and several end-point PCR assays (21-23).  Another approach that is proving to be useful for forensic DNA 
quantifications is real-time qPCR, a method widely used in biomedical research and molecular diagnostics 
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(24-27).   Quantitative PCR assays have been developed for various forensic applications, including the 
quantification of human nuclear DNA (28-30), human mitochondrial DNA (31-33), and human Y-
chromosomal DNA (30,33). 
  In this section, we describe a new duplex real-time qPCR assay for the simultaneous quantification 
of human nuclear and mitochondrial DNA in forensic samples.  This assay was designed to be of general 
utility for forensic DNA quantifications, but to be particularly useful for the post-extraction analysis of 
samples that contain highly degraded DNA.  Such samples, though not uncommon in standard casework, are 
more often encountered in instances of mass disasters, mass graves, and missing persons’ cases (34,35).  
Short tandem repeat (STR) genotyping, due to its high power of discrimination for human identification, is 
typically the analytical method of first choice.  However, the quality and/or quantity of extracted nuclear 
DNA in these degraded samples often preclude successful STR genotyping, resulting in partial or no STR 
profiles.  Such samples can then be analyzed by less discriminatory typing methods based on polymorphisms 
in hypervariable subregions I and II (HVI and HVII) of the human mitochondrial control region.  Presently, 
the initial decision as to how to proceed with analysis, either by nuclear STR or mitochondrial typing, is 
commonly based on a slot blot quantification approach that: (i) has been reported to underestimate the 
quantity of nuclear DNA in degraded samples (36) and in samples that contain high levels of microbial 
contamination (35); (ii) provides no information about the quality (fragment length) of the quantified nuclear 
DNA; (iii) provides no direct information about the quantity of human mitochondrial DNA in the sample; 
and (iv) has no predictive information on the existence of inhibitors that might interfere with the PCR.  Due 
to these quantification deficiencies, the actual forensic analysis of challenging samples often begins by 
obtaining inadequate STR typing results, and then proceeds by using any remaining extracted DNA to 
attempt mitochondrial typing.  It has been noted previously (31) that the efficiency and quality of this 
analysis procedure could be improved substantially by obtaining reliable estimates of the amounts of human 
nuclear and mitochondrial DNA in these samples prior to beginning analysis.  Based on such estimates, an 
optimal analytical approach could be selected at the outset, leading directly to optimal genotyping or 
haplotyping results and to a concomitant savings in time, labor, reagent/kit costs and extracted DNA.   
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Several recent publications have addressed exactly these issues for forensic samples, particularly for 
degraded samples.  For example, von Wurmb-Schwark et al. (37) have developed a duplex endpoint PCR 
assay to detect a nuclear target (164 bp amplicon at betaglobin) and a mitochondrial target (260 bp at ND1).  
In their assay, the endpoint PCR products were resolved and detected by capillary electrophoresis 
(CE)/fluorescence and, though the results were not claimed to be quantitative, the intensities of the nuclear 
and mitochondrial signals were shown to be useful for selecting the appropriate forensic analysis tool for the 
typing of anthropological bone samples.  Alonso et al. (33,38) have developed several qPCR assays for 
degraded and challenging samples, including a duplex assay that simultaneously quantifies human X- and Y-
chromosomes (106 bp and 112 bp targets at the amelogenin gene).  They have also developed two singleplex 
qPCR assays for quantifying the human mitochondrial genome, one with a 113 bp HVI target and the other 
with a 287 bp HVI target.  Due to the size difference between the two target sequences, they demonstrated 
that a comparison of the quantification results from these mitochondrial qPCR assays could provide 
information about the degree of DNA degradation.  Lastly, Andreasson et al. (31) have described a nuclear-
mitochondrial duplex qPCR assay.  The nuclear portion of this assay quantifies a 79 bp target at the 
retinoblastoma (RB1) gene, and the mitochondrial portion quantifies a 135 bp target spanning the junction of 
the tRNA
lys and ATP8 genes.  Their results demonstrated that the duplex qPCR approach provides useful and 
sensitive DNA quantifications while saving analyst time and often-limited DNA.  It has been noted 
elsewhere (18), however, that the choice of RB1 as a qPCR target sequence may not be ideal because cross-
species sequence homology investigations indicate that the nuclear RB1 target sequence is relatively 
conserved.  Consequently, though this assay can be expected to provide accurate results for forensic samples 
of known human origin, it has not been demonstrated to be sufficiently primate-specific to be of general 
forensic utility. 
We describe here a new nuclear-mitochondrial duplex qPCR assay developed following the same 
general approach of Andreasson et al. (31), except that we have chosen alternative nuclear and mitochondrial 
target sequences for amplification and quantification.  For the nuclear portion of the qPCR assay, we have 
chosen a target sequence that spans the repeat region of the primate-specific TH01 STR locus, a locus that 
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has been used widely for forensic applications.  This target sequence is of direct interest for quantification, 
considering that the primary reason for quantifying human nuclear DNA in forensic samples is to determine 
the amount of extract to amplify with a commercial multiplex STR PCR kit.  Our results indicate that for 
degraded samples our choice of the relatively long TH01 target sequence (~170-190 bp) leads to improved 
STR typing results, compared to results based on quantification of a short target sequence (e.g., 62 bp in the 
Applied Biosystems Quantifiler
TM qPCR kit (16)) or via slot blot hybridization.  For the mitochondrial 
portion the assay, we selected a relatively short target sequence (69 bp) in the mitochondrial ND1 gene.  This 
selection provides a sensitive means for determining the presence of human mitochondrial DNA, degraded or 
not, in forensic samples.  In addition to describing results on quantifying DNA in degraded samples, we also 
cover aspects of development of the duplex qPCR assay, and details from forensic validation studies, 
including studies of precision, reproducibility, sensitivity, species specificity, and applications to casework-
type samples. 
 
Materials and Methods 
Standards and Samples 
Pre-quantified, high molecular weight, human genomic DNA extracts obtained from Promega 
(Female-#G1521) and from Applied Biosystems (TaqMan® Control DNA) were typically used as qPCR 
quantification standards.  Pre-quantified DNA extracts obtained from Applied Biosystems (genomic DNA 
standards from the Quantifiler™ and QuantiBlot™ kits), Promega (K562 and Male-#G1471), and ATCC 
(HL60) were also used as control samples in several studies. 
Unless otherwise indicated, DNA extracts from reference, non-probative and simulated casework 
samples were obtained using the California Department of Justice casework organic extraction protocol 
(ProK/SDS digestion, phenol/chloroform extraction, then Centricon100 (Millipore) concentration into Tris-
EDTA buffer (TE
-4)).  For simulated sexual assault samples, differential extractions of sperm and epithelial 
fractions were performed using a DTT-based digestion protocol (39).  For non-root hair shafts (2 cm 
portions), extractions were performed by either (i) a magnetic-bead-based protocol (40) or (ii) a protocol in 
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which a tissue grinder was first used to homogenize the hair shaft with 150 µL TE
-4, after which the 
homogenate was extracted into 50 µL of boiling 20% Chelex (Bio-Rad).  DNA extracts were stored at -20ºC, 
except for Chelex-extracted samples, which were stored at +4 ºC. 
For degradation studies, DNA samples were fragmented by treatment with DNase I (Invitrogen).  
Separate tubes of high molecular weight HL60 DNA, each tube containing 1.4 µg of DNA in 5 µL TE
-4, were 
treated with 0.5 U of DNase I, 10x DNase I Reaction Buffer, and sterile water to bring the reaction volume to 
10 µL.  Increasing degrees of fragmentation were achieved by allowing the tubes to digest at room 
temperature for periods of 1, 2, 3, 4, 5, 15, 30, 45, 60 min and overnight.  At the end of each digestion period, 
DNase activity was quenched by adding 2 µL of 25 mM EDTA and heating each tube at 65 ºC for 15 min.  
The samples were not further purified or concentrated.  A “0 min” sample of intact DNA which contained all 
reaction components for digestion except DNase I was treated identically to the samples in the degradation 
series.  The degree of DNA fragmentation was assessed by gel electrophoresis (2% agarose, ethidium 
bromide detection) using HyperLadder I (Bioline) and Ready-Load λ-DNA/Hind III (Invitrogen) size 
markers. 
Non-human DNA samples were purchased as pre-quantified genomic DNA extracts from several 
vendors: E. coli, C. perfringens (Sigma), B. subtilis, S. epidermidis, C. albicans (ATCC), mouse (Promega), 
and cat, chicken, cow, dog, fish, horse, monkey, pig, rat (Zyagen Labs, San Diego, CA). 
 
STR Genotyping 
The AmpFlSTR® Identifiler
TM PCR Amplification kit (Applied Biosystems) was used for STR 
genotyping.  PCR amplifications of 1 ng of nuclear DNA in a 25 µL reaction volume were performed 
according to vendor instructions on a GeneAmp® 9700 PCR thermocycler (Applied Biosystems).  STRs 
were resolved and detected on a Prism® 3100 Genetic Analyzer (Applied Biosystems) according to vendor 
instructions, except that the electrokinetic sample injection time was dropped from the default of 10 seconds 
to 5 seconds, and the data were analyzed with a baseline of 35 rather than the default of 51.  Alleles were 
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identified at a minimum threshold of 100 RFU using GeneScan® (v.3.7.1/NT) and Genotyper® (v.3.7/NT) 
(Applied Biosystems) for data analysis. 
 
Mitochondrial HVI/HVII PCR 
The mitochondrial control regions of HVI and HVII were amplified in a duplex PCR using reagents 
from the LINEAR ARRAY
™ Mitochondrial DNA HVI/HVII Region-Sequence Typing Kit (Roche Applied 
Science) (41,42).  This kit produces nominal 444 bp (HVI) and 416 bp (HVII) amplicons.  Template 
quantities for PCR were determined either from our nuTH01 duplex qPCR assay (using 100 pg of nuclear 
DNA per duplex HVI/HVII amplification) or from our mtND1 duplex qPCR assay to quantify the 
mitochondrial genome (using ~14,000 mitochondrial copies per duplex HVI/HVII amplification).  Post-
amplification yields and purities of the HVI and HVII PCR products were assessed by gel electrophoresis 
(4% NuSieve 3:1 (FMC) agarose gel, ethidium bromide staining) of 5 µL of PCR product using Low DNA 
Mass Ladder (Invitrogen) as a size and quantity marker. 
 
Slot Blot Quantification 
   The QuantiBlot
TM Human DNA Quantification Kit (Applied Biosystems) was used according to 
vendor instructions.  Hybridized probes were detected by chemiluminescence (SuperSignal West Femto 
(Pierce)) using a CCD camera system (CCDBio 16SC (Hitachi/MiraiBio)).  CCD data were analyzed semi-
automatically using SlotQuant software running under the GeneTools (SynGene) analysis package.  
Quantification standards (DNA Standard A from the kit) ranged from 20 ng to 25 pg for each run.  
 
Quantifiler™ qPCR Quantification   
The Quantifiler™ Human DNA Quantification Kit (Applied Biosystems), hereafter referred to as 
“Quantifiler
TM qPCR,” was used according to vendor instructions for data collection on an Applied 
Biosystems 7000 Prism® SDS qPCR instrument. 
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qPCR Assay Design 
Primers and probes (Table 2) for the nuTH01 TaqMan® and mtND1 TaqManMGB® (MGB = Minor 
Groove Binder) singleplex qPCR assays were designed using Applied Biosystems’ PrimerExpress™ v2.0 
software.  In general, design guidelines were followed as recommended by Applied Biosystems (43), 
although the software settings in PrimerExpress
TM were frequently relaxed to allow amplicon lengths to 
exceed the recommended maximum length of 150 bp.  DNA sequences for design work were downloaded 
from the GenBank resource at the National Center for Biotechnology Information (NCBI) website (44).  
Sequence information was also obtained from the STRBase (45) and MitoMap (46) websites.   
 
TABLE 2 – Oligonucleotide sequences for nuTH01 primers and probe, and for mtND1 primers, probe, and 
mitochondrial copy number standard. 
 
 
Oligonucleotide    Sequence  {5’Æ 3’} 
 
 
nuTH01-F     AGG GTA TCT GGG CTC TGG 
nuTH01-R     GGC TGA AAA GCT CCC GAT TAT 
nuTH01-probe     FAM-ATT CCC ATT GGC CTG TTC CTC CCT T-BHQ 
mtND1-F     CCC TAA AAC CCG CCA CAT CT 
mtND1-R     GAG CGA TGG TGA GAG CTA AGG T 
mtND1-probe     VIC-CCA TCA CCC TCT ACA TC-MGB-NFQ 
mtND1-standard  GAG CGA TGG TGA GAG CTA AGG TCG GGG CGG 
TGA TGT AGA GGG TGA TGG TAG ATG TGG CGG 
GTT TTA GGG 
_______________________________________________________________________________________ 
 
The nuclear qPCR assay (nuTH01) was designed to span the STR sequence at the human tyrosine 
hydroxylase (TH01) gene on chromosome 11 (11p15.5) using sequence from GenBank locus AF536811.  In 
this design work, we configured PrimerExpress™ to fix the positions of the 3’ ends of the qPCR primers so 
as to match known or deduced primers from commercial STR amplification kits (47, 48).  This was done so 
that the qPCR amplifications might more accurately predict quantifications for STR genotyping.  The 
positions of the fluorogenic probe and the 5’ ends of the primers were typically unconstrained for 
optimization by PrimerExpress™.  The mitochondrial qPCR assay (mtND1) was designed in the ND1 gene 
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of the human mitochondrial genome using sequence from Genbank locus HUMMTCG (49).  The ND1 gene 
expresses subunit 1 of the mitochondrial NADH dehydrogenase protein.   
For both the nuclear and mitochondrial assays, prior to ordering any synthetic oligonucleotides for 
experimental work, potential primer and probe sequences were compared to DNA sequences available 
through the NCBI website by using the Basic Local Alignment Search Tool (BLASTn) (50).  The purpose of 
these comparisons was to identify and avoid inadvertent homologies of primers and/or probes to non-target 
genomes that might lead to undesirable cross-species reactivities.  In addition, attempts were made to avoid 
known single nucleotide polymorphisms (SNPs) in the primer and/or probe sequences.  SNP information was 
obtained from several sources: the NCBI SNPdB website (51), the On-Line Mendelian Inheritance in Man 
(OMIM) website (52), and, for mitochondrial sequences, the MitoMap website (46).  Once developed, 
singleplex and duplex qPCR assays were optimized based on published recommendations (53,54). 
 
nuTH01-mtND1 qPCR Quantifications 
Primer and probe sequences for the nuTH01 and mtND1 qPCR assays are provided in Table 2.  For 
nuTH01-mtND1 duplex qPCR amplifications, each assay was run as a 20 µL amplification that included 10 
µL of TaqMan® Universal Master Mix 2X, no UNG (Applied Biosystems), 4 µL of sample, with the 
remaining 6 µL composed to give final concentrations of: 0.16 µg/µL non-acetylated BSA (Sigma); 600 nM 
in each nuTH01 primer; 200 nM in nuTH01-probe; 50 nM in each mtND1 primer; 100 nM in mtND1-probe.  
Primers (Qiagen-Operon (Alameda, CA)) were diluted in sterile, de-ionized water.  Probes (Qiagen-Operon 
for nuTH01, Applied Biosystems for mtND1) were diluted in TE
-4. 
For nuTH01 and mtND1 singleplex TaqMan®/TaqManMGB® qPCR amplifications, assays were 
run using the same reagents as described for the duplex qPCR assay, except to replace the non-desired 
primer/probe combination with sterile water or TE
-4.  Singleplex SYBR® Green I assays were typically run 
as 20 µL amplifications that included 10 µL of 2X SYBR® Green Master Mix (Applied Biosystems) or 10 
µL of 2X Brilliant® QPCR Master Mix (Stratagene), 4 µL of sample, with the remaining 6 µL composed to 
give final concentrations of 300 nM in each appropriate primer. 
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Real-time qPCR data were collected on an Applied Biosystems Prism® 7000 SDS instrument 
controlled by a computer running version 1.0 of the 7000 SDS Collection software.  The instrument was 
typically configured for the following run conditions: 20 µL sample volumes; 9600 emulation mode; one 10 
minute 95 ºC polymerase activation step, followed by 45 cycles of 2-step qPCR (15 s of 95 ºC denaturation, 
60 s of 60 ºC combined anneal/extension).  Well-to-well variations in background fluorescence were 
corrected for by use of a ROX-labeled passive reference, included as part of the Applied Biosystems qPCR 
Master Mix for each sample.  For runs that used SYBR® Green detection, a melt curve was collected after 
the final cycle of PCR extension by configuring the SDS Collection software to monitor SYBR® Green 
fluorescence as the temperature was increased (~1.8 ºC /min) from 60 ºC to 95 ºC.     
Amplification curves were analyzed by using empirically established cycle threshold and baseline 
settings for each type of assay (for nuTH01, cycle threshold = 0.15, baseline 6-18 cycles; for mtND1, cycle 
threshold = 0.06, baseline 3-13 cycles).  For each qPCR run, the SDS Collection software generated a linear 
calibration plot of CT (cycle threshold) vs. log C0 (initial standard DNA concentration) by using 
amplification results from a freshly prepared dilution series of pre-quantified high molecular weight human 
genomic DNA standard (Promega Female or Applied Biosystems TaqMan®).  DNA quantifications for 
unknown samples were interpolated from the resulting linear calibration curve.  These calibration and 
interpolation steps are semi-automatic features of the SDS Collection software.  For the nuclear qPCR assay, 
calibration plots were constructed using data from standard DNA dilutions containing 25, 5, 1, 0.5, 0.1, and 
0.05 (in duplicate) ng of total DNA per sample.  For the mitochondrial qPCR assay, the calibration plots 
were extended to lower quantities of template per sample (0.010, 0.001, and 0.0001 (in duplicate) ng).  At 
least one negative control, 4 µL of TE
-4 or sterile water, was included in each run.   
Nuclear DNA copy numbers were estimated using the ratio of one haploid nuclear copy per 3.3 pg 
genomic DNA (55).  Mitochondrial copy numbers were estimated using a ratio of 400 mitochondrial copies 
per 3.3 pg of Promega genomic standard DNA or 450 mitochondrial copies per 3.3 pg of HL60 genomic 
standard DNA.  These mitochondrial copy number ratios were empirically estimated by running the Promega 
and HL60 standard DNA samples against a dilution series of quantified (UV-vis absorption) mtND1 
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synthetic oligonucleotide standard (see Table 2 for oligonucleotide sequence of the mitochondrial copy 
number standard).  For each qPCR run, we used the high molecular weight genomic DNA dilution series to 
generate two linear calibration plots, one for the nuclear portion and one for the mitochondrial portion of the 
duplex assay. 
 Where appropriate, qPCR amplification efficiencies were determined from the slopes of the linear 
calibration curves (% PCR efficiency = 100[(10
(-1/slope) - 1)]) (56). 
 
Oligonucleotide Melting Profile Calculations 
Melting profiles for selected TH01 alleles were calculated using MELT94, a DOS-based program 
available on-line (57).  This program uses the theory and equations of Poland (58) and of Fixman and Freire 
(59) to calculate variations in thermal stability along the sequence of a DNA fragment (60).  Stacked melting 
profiles were constructed by exporting MELT94 output data (temperatures for 50% helical:50% melted states 
vs. sequence number) into an Excel® spreadsheet. 
 
Results and Discussion 
 
Design and Development of the nuTH01-mtND1 Duplex qPCR Assay 
In the preceding Materials and Methods section of this report we included a brief outline of the 
procedures used to design our singleplex nuclear (nuTH01) and mitochondrial (mtND1) qPCR assays.  In 
this section, we provide a more detailed discussion of selected aspects of assay design and development, 
including: (i) choices of target DNA sequences; (ii) experimental results to establish that the singleplex 
nuTH01 and mtND1 qPCR assays work successfully in a duplex amplification; and (iii) the observation of 
unusual, but predictable, SYBR® Green melt curves for the TH01 qPCR target. 
 
Selection and Design of the Nuclear TH01 Amplification Target 
Because the primary reason for quantifying nuclear DNA in forensic samples is to determine the 
amount of template to use as input for STR genotyping, we anticipated that the quantification of an STR 
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target would be directly predictive of success for STR genotyping.  Furthermore, STR loci have been well 
characterized with respect to cross-species reactivity (61,62) and DNA mutation rates (63) because of their 
widespread use in forensic DNA analysis and in paternity investigations.  Although initially we did not focus 
solely on the TH01 locus for assay development, an examination of the DNA sequences at each of the 
CODIS STR loci, in conjunction with assay design work using PrimerExpress™, quickly identified the 
TH01 locus as a promising target.  The TH01 locus contains suitable sequence in both STR flanking regions 
for design and placement of a TaqMan® detection probe.  The TH01 STR target was also attractive because 
the amplicons are of sufficient lengths to place them roughly in the middle of the size range produced by the 
commercial STR kits, but are not long enough to overly compromise the TaqMan® qPCR efficiency.  
During development, we designed and tested a number of potential qPCR assays at the TH01 STR locus.  
These assays were evaluated by comparing their qPCR properties (e.g., PCR efficiency (> 90 %), sensitivity 
(low CT), and precision (low variance in CT, especially at low template quantities)) in order to identify an 
optimal assay, designated here as nuTH01.  The target sequence for the nuTH01 qPCR assay is shown in 
Figure 4, which displays the relative positions of the PCR primers, the STR repeat region, and the 5’-
FAM/BHQ fluorogenic probe. 
 
 
 
 
 
 
 
 
FIG. 4 - Sequence information for the nuTH01 portion of the duplex qPCR assay showing relative positions 
of the forward and reverse primers (horizontal arrows), the TaqMan® detection probe (underlined on top 
strand), and the (CATT)7 STR region (underlined on bottom strand).  The small, vertical arrow marks the 
sequence position that approximately separates the nuTH01 amplicon into low and high melting temperature 
domains.  The position of this arrow corresponds to Sequence Number 96 in Figure 8. 
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Selection and Design of the Mitochondrial ND1 Amplification Target 
  For design of the mitochondrial qPCR assay, we selected a region of the ND1 (NADH 
dehydrogenase subunit 1) gene corresponding to bases 3485-3553 of the Cambridge Reference Sequence 
(CRS) (64).  This target was chosen because previous cross-species sequence homology studies (65, and 
personal communication with Cummings MP) had indicated this sub-region of the ND1 gene to be 
significantly non-conserved, a promising feature for developing a species-specific assay, and because this 
region of ND1 has few known SNPs, especially when compared to the HVI/HVII control sub-regions.  Using 
a number of web-based searching tools and avoiding any well-known disease-associated SNPs such as the 
LHON-associated SNP at CRS 3460, we designed and evaluated several assays at the ND1 target.  Using the 
same criteria as for the nuTH01 qPCR assay, we selected an optimal mitochondrial qPCR assay, designated 
mtND1 (Table 2).   
The mtND1 assay quantifies a relatively short (69 bp) target sequence, one strand of which is shown 
in Table 2 as the sequence for our mtND1 copy number standard.  One advantage to selecting an assay with a 
short target sequence was that it allowed purchase of a synthetic oligonucleotide which could then be used as 
a copy number standard for the mitochondrial assay, rather than preparing a standard by cloning or PCR 
product purification.  Also, we anticipated that a short qPCR assay would detect more sensitively the 
presence of human mitochondrial DNA, even in degraded DNA samples.   
 
Development of the nuTH01-mtND1 Duplex qPCR Assay 
In order to develop a successful duplex qPCR assay, it is necessary to identify reaction conditions 
that effectively allow two amplifications to occur independently in the same tube.  The goal is to avoid the 
predicament in which one of the amplifications reduces the PCR efficiency of the second amplification.  
Such a situation can lead to a delayed amplification for the second assay, an artificially large CT value, and a 
corresponding underestimation of the quantity of target DNA measured by that assay.  One strategy for 
avoiding this situation is to develop duplexed qPCR assays to run under conditions that limit PCR 
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amplification of the more abundant target sequence, for example by limiting the primer and/or probe 
concentrations for this amplification (54). 
For the nuTH01-mtND1 duplex qPCR assay, we expected that the ratio of mitochondrial genome 
copies to haploid nuclear genome copies would normally exceed 100 for relevant forensic samples.  This 
expectation was based on literature reports of mitochondrial-to-nuclear copy number ratios for various tissue 
types (66,67).  Consequently, our approach for developing a duplex assay relied on finding appropriate 
limiting conditions for the mtND1 qPCR portion of the assay, while running the nuTH01 portion under 
optimized conditions.  The development was accomplished in several steps (54).  The nuTH01 singleplex 
qPCR assay was first examined at a range of primer (50-900 nM) and probe (50-300 nM) concentrations to 
determine optimal conditions for the assay.  These experiments indicated that optimal sensitivity (low CT) 
and precision (low standard deviation of CT) were obtained by running the nuTH01 assay with 600 nM 
primer and 200 nM TaqMan® probe concentrations.  We similarly examined the mtND1 singleplex qPCR 
assay at a range of primer (25-900 nM) and probe (25-200 nM) concentrations to determine that adequate 
sensitivity and precision could be obtained by running this assay with 50 nM primer and 100 nM 
TaqManMGB® probe concentrations.  Our goal of running the mtND1 assay at limiting conditions is evident 
from the very different primer concentrations identified for the two singleplex qPCR assays.  In order to 
determine if these reaction conditions were suitable for duplex qPCR amplifications, we compared results 
obtained by quantifying identical samples in both singleplex and duplex qPCR formats (Figure 5).  This 
comparison indicated that the qPCR assays, whether run in singleplex or in duplex, gave nearly identical 
quantifications and efficiencies.    The nuTH01 qPCR assay neither lost efficiency nor showed a delayed CT 
when run in duplex vs. singleplex.  (Due to a small amount of “leakage” of the VIC fluorescence signal into 
the FAM detection channel, the nuTH01 qPCR assay actually appeared to amplify with a slightly lower CT 
when run in duplex than when run in singleplex format.)  As a final developmental step, we challenged the 
duplex assay by spiking a 3 ng control sample of DNA with increasing amounts of synthetic oligonucleotide 
mtND1 copy number standard, adding up to a one-billion-fold excess number of effective mitochondrial 
copies to the original DNA sample.  As shown in Figure 6, the nuTH01 amplification curves and the 
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corresponding CT values did not change significantly, even in the presence of an unrealistic excess of 
mitochondrial copies. 
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FIG. 5 - Standard curves for nuTH01 and mtND1 qPCR assays run in singleplex and in duplex modes.  For 
the nuTH01 qPCR assays, the data points shown are averages of duplicate measurements on samples 
containing 3.2, 0.8, 0.2, 0.05 and 0.005 ng of Promega genomic DNA (female).  For the mtND1 qPCR 
assays, duplicate measurements on samples containing 0.0005 ng of DNA were also included.  The PCR 
efficiency for each assay was calculated using the slope of the CT v. log C0 standard curve. 
 
 
FIG. 6 - qPCR amplification curves for nuTH01-mtND1 duplex assays with 3 ng of control DNA plus 0, 10
6, 
10
7, 10
8, and 10
9 excess copies of single-stranded mtND1-standard.  Assays were run in duplicate. 
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Because we designed the duplex qPCR assay to limit the mtND1 amplification conditions while 
running the nuTH01 amplification under robust conditions, the duplex assay was not optimized for samples 
in which the number of nuclear genome copies is nearly equivalent to or greater than the number of 
mitochondrial genome copies.  For such samples, the more robust nuTH01 amplification can lower the 
efficiency of the mtND1 amplification, resulting in an underestimation of the quantity of mitochondrial 
DNA.  So far, we have encountered only one type of forensic sample - the largely tail-less sperm cells from 
differential extraction pellets - in which the ratio of mitochondrial genome copies to nuclear genome copies 
is not large.  Although such samples are not commonly used for mitochondrial haplotyping, this limitation of 
the assay should be kept in mind when interpreting mtND1 quantification data. 
 
TH01 SYBR® Green Melt Curves 
  The selection of a qPCR target sequence that spans the repeat region of an STR locus introduces the 
possibility that the resulting assay will depend in some way upon the STR genotype, for example, that the 
nuTH01 assay will give measurably different results for a 6,6 TH01 genotype than for a 9,9.3 TH01 
genotype.  We have not, within the precision and accuracy of our quantification experiments, seen any such 
effects for our nuTH01 qPCR assay.  The only allele-dependent effect that we have seen was the observation 
of unusual SYBR® Green melt curves.  While this effect has no detrimental impact on the quality of TH01 
qPCR assay, it is novel and requires an explanation. 
In initial developmental experiments, each potential assay was evaluated by performing qPCR runs 
using SYBR® Green I detection.  This detection method allows for early identification of sub-optimal primer 
combinations, avoiding use of the more expensive, dye-labeled TaqMan® detection probes.  As part of these 
initial assessments, we evaluated the specificity of the PCR amplifications by gel electrophoresis (4% 
NuSieve 3:1 agarose gel with EtBr staining) of the post-run qPCR reaction mixtures and by using the qPCR 
instrument to generate SYBR® Green melt curves.  During this developmental work, for each of our 
potential TH01-based qPCR assays, we observed unusual SYBR® Green melt curves (Figure 7). 
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(d)   6,  9 
(a),(b)   6, 6 
(c)   6,  7 
(e)   8,  9.3 
(f)   9,  9.3 
(g)   TE-4 
FIG. 7 - SYBR® Green melting curves obtained for DNA extracts from six different individuals and a 
negative control sample using the TH01 qPCR assay.  The TH01 genotype for each sample is indicated.  
Traces (a) and (b) are from two different individuals, both genotype 6,6 at TH01. 
 
For qPCR assays detected with SYBR® Green, a melt (or dissociation) curve can be generated at the 
end of the final PCR cycle by configuring the qPCR instrument to monitor the SYBR® Green fluorescence 
of each sample as the temperature is slowly increased from ~60 ºC (the extension temperature of the final 
PCR cycle) to ~95 ºC.  At temperatures corresponding to the melting of PCR products there will be 
concomitant decreases in SYBR® Green fluorescence due to de-intercalation of the reporter dye.  In order to 
easily visualize these changes in fluorescence, melt curves are typically plotted as the negative first 
derivative of the change in fluorescence (-dF/dT) so that each “melt transition” will appear to be a single 
peak in the plot.  A well-designed qPCR assay is expected to produce a single amplicon and, typically, a 
single transition in the SYBR® Green melt curve. 
  Figure 7, which shows the SYBR® Green melt curves collected for several different samples using 
the TH01 qPCR assay, indicates that each sample shows not one, but two melt transitions - a high melting 
temperature major peak (Tm ~ 81 ºC) and a lower melting temperature “shoulder” (Tm ~ 78-79 ºC).  This 
observation of two melt transitions was not anticipated because the TH01 qPCR assay was otherwise 
unremarkable; it showed evidence for only one PCR product in post-amplification yield gels, and there was 
no evidence for spurious melt transitions in any negative controls.  The two-step appearance of the melt 
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transitions suggests the presence of two sequence-dependent melting domains in each TH01 amplicon.  This 
suggestion is supported by calculations of allele-dependent melting profiles for the amplicons performed 
with a software package, MELT94, which uses sequence information to estimate the melting temperature of 
a DNA fragment along its double-stranded length (Fig. 8).  Such calculations separate the TH01 amplicon 
into two distinct melting domains - a low melting temperature domain that includes the STR region 
(Sequence Number 0-~96) and a high melting temperature domain (Sequence Number ~96-~180).  These 
calculations predict that the melting temperature of the low-melt domain will decrease as the number of 
STRs increases (Fig. 8, inset), a prediction that is in qualitative agreement with the trend seen for the 
experimental melting curves shown in Figure 7.  This trend is due to an increase in the AT-percentage of the 
low-melting domain sequence as the number of CATT repeats increases.  The melting profile of the high-
melt domain is predicted to be independent of the TH01 genotype (Fig. 8), consistent with the allele-
independent, overlapping melt transitions (Tm ~81 ˚C) shown in Figure 7. 
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FIG. 8 - Calculated melting profiles for TH01 amplicons (STR alleles 5-10) as generated by MELT94 
software.  Sequence Number 96 corresponds to the position of the small, vertical arrow in Figure 4.  The 
inset figure shows an expansion of the melting profiles in the STR region. 
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The stepwise melting of small DNA fragments due to sequence-dependent melting domains has been 
reported (68), and similar sequence-dependent denaturation phenomena form the basis for separations by 
such techniques as denaturing gel gradient electrophoresis (DGGE) (69).  To our knowledge, however, 
genotype-dependent stepwise melt transitions have not been previously reported for STR amplicons.  It is 
intriguing that the SYBR® Green melt curves for the TH01 qPCR assay might form the basis for a fairly 
simple and rapid, albeit low-resolution, means for STR genotyping at this locus, as well as at other STR loci 
that show similar allele-dependent melt curves. 
 
nuTH01-mtND1 Duplex qPCR Validation:  Precision, Sensitivity, and Reproducibility 
Precision of the nuTH01-mtND1 duplex qPCR assay was assessed by running 96 identical assays in 
a single wellplate using 4 ng of pre-quantified standard DNA (Promega Human Genomic Female DNA) per 
quantification.  For the nuTH01 portion of the duplex assay, we measured an average CT of 28.94 cycles 
with a standard deviation (SD) of 0.13 cycles and a CT range of 0.59 cycles.  For the mtND1 portion of the 
assay, we measured an average CT of 22.63 cycles with a SD of 0.21 cycles and a CT range of 0.98 cycles.  
No systematic deviations in CT across rows or columns of the 96-well plate for either portion of the duplex 
assay were observed.  Although we did not include a standard DNA dilution series in this run, the standard 
deviation of CT can be used to estimate the relative standard deviation (RSD or %CV) of genome copy 
number as 100(2
(SD of CT)-1); this estimation assumes 100% PCR efficiency for the assay.  By this means, we 
estimate the intra-plate RSD of genome copy number to be ~10% for the nuTH01 assay and  ~16% for the 
mtND1 assay. 
  Sensitivity of the duplex qPCR assay was assessed by quantifying Promega Human Genomic Female 
standard DNA using template quantities ranging from 100 ng to 1 fg.  All quantifications were performed in 
replicates of five in order to estimate the minimum level of input DNA at which stochastic effects (e.g., 
qPCR signal dropout and reduced quantification precision) can be expected to become significant.  Results 
from these runs are summarized in Table 3.  As expected, these results indicate that as the number of 
template copies diminishes, there is a general decrease in precision for both the nuTH01 and mtND1 portions 
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of the duplex assay.  For the nuTH01 portion of the qPCR assay, adequate levels of precision (<30% RSD) 
are seen down to approximately 50 pg of template DNA (~15 haploid nuclear copies), and we have generally 
seen similar levels of precision down to approximately 32 pg or ~10 copies (data not shown).  At lower 
quantities of nuclear template, loss of precision, as well as an increase in the proportion of “dropped out” 
amplification curves occurred (e.g., 20% of the nuTH01 qPCR assays dropped out and were undetected at 10 
pg of template, 30% at 5 pg, 80% at 1 pg, and 100% at <1 pg).  This is probably due to stochastic effects in 
sampling and in amplification at low levels of template.  For the mtND1 portion of the qPCR assay, adequate 
levels of quantification precision (<40% RSD) were seen down to at least 100 fg of nuclear template, which 
corresponds to ~12 mitochondrial template copies for the Promega genomic female standard DNA.  All 
mtND1 qPCR amplification curves dropped out at 10 fg of nuclear template. 
 
TABLE 3 - Intra-run sensitivity and precision results for the nuTH01-mtND1 duplex qPCR assay.  Results 
are based on five replicate quantifications of serially diluted Promega Female Genomic DNA standards.  
Quantities are per 4 µL of sample.  Standard deviations are in parentheses. 
 
 
 
 
nuTH01 qPCR    mtND1 qPCR 
 
Input DNA 
Quantity 
(ng) 
 
 
Average 
Quantity 
(ng) 
 
 
 
RSD 
(%) 
Approx. 
Input 
Quantity  
(mt copies) 
 
Average 
Quantity 
(mt copies) 
 
 
 
RSD 
(%) 
100  95.8 (7.7)  8.0  1.2 x 10
7 8.6 (0.97) x 10
6 11 
10  10.7 (0.90)  8.4  1.2 x 10
6 1.3 (0.15) x 10
6 12 
5  4.7 (0.088)  1.9  6.1 x 10
5 7.6 (0.95) x 10
5 12 
1  1.2 (0.034)  3.0  1.2 x 10
5 1.3 (0.24) x 10
5 18 
0.5  0.48 (0.057)  12  6.1 x 10
4 7.1 (1.4) x 10
4 20 
0.1  0.10 (0.021)  21  1.2 x 10
4 1.0 (0.20) x 10
4 20 
0.05  0.051 (0.013)  26  6.1 x 10
3 7.2 (1.5) x 10
3 21 
0.01  0.0057* (0.0017)  30*  1.2 x 10
3 1.3 (0.21) x 10
3 17 
0.005  -  -  6.1 x 10
2 7.1 (2.0) x 10
2 28 
0.001  -  -  1.2 x 10
2 1.1 (0.39) x 10
2 35 
0.0001  -  -  1.2 x 10
1 1.1 (0.41) x 10
1 39 
 
* Based on four replicates, because one quantification dropped out at this template quantity. 
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Reproducibility of the duplex assay was assessed by comparing quantifications of six different high 
molecular weight control DNA samples obtained from three independent qPCR runs as performed by two 
different analysts on two different days.  Samples were quantified as single replicates in each run.  The 
results are summarized in Table 4, where we estimate “reproducibility” as the effective RSD for each sample 
by pooling the quantification results from the three runs.  These inter-plate RSD values are, on average, in 
reasonable agreement with the intra-plate RSD values reported in our discussion of assay precision and 
sensitivity.  A notable exception is the single large RSD (62%) observed for the mtND1 quantification of 
sample A. 
TABLE 4 - Inter-run reproducibility results for nuTH01-mtND1 duplex qPCR quantifications of six 
commercial high molecular weight genomic DNA standards (samples A-F).  Slot blot quantities are based on 
single replicate measurements for each sample.  qPCR quantities are reported as averages, based on pooling 
the results from the three single-replicate qPCR runs.  Standard deviations are in parentheses.  Promega 
Genomic Female DNA was used as the quantification standard for all three qPCR runs. 
 
 
 
 
 
 
nuTH01 qPCR 
 
mtND1 qPCR 
 
 
 
 
Sample 
 
 
Slot Blot 
Quantity 
(ng/µL) 
 
Average 
Quantity 
(ng/µL) 
 
 
RSD 
(%) 
Average 
Quantity 
(1000 mt 
copies/µL) 
 
 
 
RSD 
(%) 
 
A  0.85  0.64 (0.08)  12  130 (79)
  62 
B  0.80  0.96 (0.10)  10  880 (150)
  17 
C  0.34  0.53 (0.10)  20  310 (35)
  11 
D  1.31  1.58 (0.31)  19  430 (31)
  7 
E  0.97  1.51 (0.17)  11  790 (170)
  21 
F  0.40*  0.45 (0.05)  12  360 (73)
  21 
 
* Sample F represents the calibration standard used for the slot blot quantifications; the  value for 
sample F (0.40 ng/µL) is a defined, rather than a measured quantity. 
 
nuTH01-mtND1 Duplex qPCR Validation:  Species Specificity 
To assess species specificity of the nuTH01 and mtND1 qPCR amplifications, the duplex assay was 
run using template DNA from each of fifteen different non-human species.  Duplicate assays, each 
containing 1 ng of template, were used for each species.  No cross-reactivity to non-human DNA was 
observed for either the nuTH01 or mtND1 portions of the duplex qPCR assay.  We further challenged the 
duplex assay by amplifying 100 ng portions of each of the microbial DNA samples, and we observed no 
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amplifications above the level of background in either the nuTH01 or mtND1 quantifications.  These results 
indicate that the nuTH01-mtND1 duplex qPCR assay is sufficiently specific for forensic applications.  
Although we did not test the assay with DNA from higher primates, based on previous work with the TH01 
STR locus (61,62) and on sequence homology investigations, we anticipate that the nuTH01 qPCR assay 
would amplify and detect such samples. 
 
nuTH01-mtND1 Duplex qPCR Validation:  Degraded DNA 
Forensic evidence samples often contain DNA that has been degraded by environmental and/or 
microbial exposures.  To assess the ability of the nuTH01-mtND1 duplex qPCR to quantify DNA in such 
samples, a DNA degradation series was prepared by treating aliquots of high molecular weight genomic 
DNA (HL60) with DNase I for increasing periods of time ranging from one minute to overnight.  Figure 9 
shows a gel illustrating the degree of DNA fragmentation for the DNase-treated samples.  An increase in the 
degree of DNA fragmentation during the first 5 minutes of DNase treatment is evident from increased 
intensity of the low molecular weight “smear” in lanes 3 to 7 of the gel.  During this time, the extent of 
degradation is best described as “moderate” given the consistent appearance of a fairly intense high 
molecular weight band in these lanes.  For samples with at least 15 minutes of DNase treatment, however, 
there is no evidence for the high molecular weight band.  For the purpose of this discussion, we describe 
these samples as “highly degraded.”   
LH   0    1    2    3   4    5   15  30 45  60  LD  LH 
10 kbp 
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FIG. 9 - HL60 DNase degradation series  
(EtBr-stained).  Lanes labeled 0 to 60 indicate DNase 
treatment time in minutes.  Lanes labeled LH and LD 
 represent λ-HindIII and low-mass DNA ladder,  
respectively. 
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  Samples from the DNA degradation series were quantified by three different methods: slot blot 
hybridization, nuTH01-mtND1 duplex qPCR, and the Applied Biosystems Quantifiler
TM Human DNA 
Quantification kit.  Because the nuTH01 assay amplifies a ~170-190 bp target sequence, while the 
Quantifiler
TM kit amplifies a 62 bp target sequence, we included the Quantifiler
TM assay in our comparison as 
a means to evaluate the significance of amplicon size for quantifying degraded DNA.  For the qPCR assays, 
2 µL of diluted sample (1:20 in TE
-4) were quantified in duplicate for each point in the degradation series.  
For the slot blot assays, single quantifications were obtained on 4 µL of the same diluted samples.  
Quantification results (nuclear quantifications only) for the three methods are summarized graphically in 
Figure 10, from which a number of conclusions can be drawn.  First, for undigested, high molecular weight 
DNA (0 min sample), the three methods provide quantifications that are in good agreement with each other, 
as well as in reasonable agreement with the concentration (~6 ng/uL) estimated for a 1:20 dilution of the 
DNA stock.  Second, for the moderately degraded samples (1-5 min of DNase treatment), the two qPCR-
based quantification methods are in good agreement, but both give quantification values significantly higher 
than those obtained from the slot blot method.  Third, for highly degraded samples (>15 min of DNase 
treatment), none of the quantification methods agree.  Relative to both qPCR-based methods, the slot blot 
method detects significantly less DNA.  Even the nuTH01-mtND1 duplex and Quantifiler
TM qPCR assays 
disagree, the latter assay detecting significantly more DNA than the former. 
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FIG. 10 - Nuclear quantifications of DNase-degraded HL60 samples by nuTH01-mtND1 duplex qPCR, 
Quantifiler
TM qPCR, and slot blot hybridization.  For the qPCR assays, each point represents the average of 
duplicate quantifications.  For slot blot, each point represents a single quantification.  Lines represent linear 
least-squares fits to early (0-5 min) and late (15-45 min) time points in the degradation series. 
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  These results, which indicate that the quantity of DNA measured in degraded samples depends upon 
the quantification method used, were not entirely unexpected.  There have been previous reports that the slot 
blot method underestimates the quantity of nuclear DNA in degraded or compromised samples (28,35,36), 
and it has been suggested that this effect is due to a lowered binding efficiency of the degraded DNA 
fragments to the slot blot membrane (28).  Some degree of difference in quantifying degraded DNA by qPCR 
was also to be expected, considering the size difference between the target sequences for the nuTH01 and 
Quantifiler
TM assays.  The Quantifiler™ qPCR assay effectively measures the concentration of nuclear DNA 
fragments at least 62bp long, whereas the nuTH01 qPCR assay measures the concentration of fragments at 
least 170-190bp long.  For high molecular weight DNA samples these two concentrations are practically the 
same, but for highly degraded DNA samples there is a greater concentration of smaller than larger fragments.  
This concentration difference is indicated by the yield gel shown in Figure 9 and is reflected in the divergent 
DNA quantities measured by the Quantifiler
TM and nuTH01 qPCR assays. 
  The primary reason for accurately quantifying nuclear DNA in forensic samples is to ensure the 
correct amount of template is used for STR amplification.  When too little template DNA is amplified, 
incomplete STR profiles can result, while amplification of excess template can cause such problems as poor 
inter-locus balance, increased stutter peak intensities, incomplete non-template-directed nucleotide addition, 
off-scale signals, and signals due to cross-dye “pull-up,” each of which can complicate or preclude accurate 
STR genotyping.  For degraded samples, as we have seen, different quantification methods can provide very 
different estimates of DNA quantity.  To investigate the implications of these differences, we attempted to 
determine which of the three quantification methods would provide the most suitable estimates of nuclear 
DNA quantity for STR typing of degraded samples.  To this end, we used the quantification results shown in 
Figure 10 to prepare nominal “1ng” portions of nuclear DNA for each time-point in the DNase-degradation 
series based on each of the three quantification methods.  These “1ng” portions were then amplified and 
genotyped using the AmpFlSTR®  Identifiler
TM STR kit. 
Figure 11 provides a qualitative, graphical overview of the STR genotyping results for the entire set 
of DNase-degraded samples.  Panel (A) in this figure suggests that for untreated and moderately degraded
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* O = off-scale peak; P = detected pull-up signal; S = detected stutter signal; A = detected shoulder due to incomplete A addition
FGA
nuTH01-mtND1 qPCR
Quantifiler qPCR
Slot Blot Hybridization
DNase 
Treatment
Percent of 
STR Alleles 
Detected
Number of STR 
Artifacts*
THO1 D13 TPOX D18 D8 D21 D7 CSF
Blue (FAM) STRs Green (VIC) STRs Yellow (NED) STRs Red (PET) STRs
 
FIG. 11 - Overview of AmpFlSTR® Identifiler
TM STR results obtained for DNase-degraded HL60 DNA samples.  Each shaded rectangle indicates the 
detection of an STR allele with intensity at least 100 RFU.  Un-shaded rectangles indicate alleles that were undetected at the 100 RFU analytical 
threshold.  For each reporter dye, the Identifiler
TM alleles are presented left to right in order of increasing size.  STR amplifications used nominal 1 
ng input levels of nuclear DNA, as quantified by the nuTH01-mtND1 duplex qPCR assay (panels A and B), by the Quantifiler
TM assay (panels A and 
C), or by slot blot hybridization (panels A and D). 
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DNA samples (0-5 min DNase treatment), all three methods were suitable for quantifying nuclear DNA for 
STR genotyping.  At these moderate levels of degradation, regardless of the method of quantification, all 
STRs were detected with signals greater than 490 RFU per locus, and there was no evidence of artifacts that 
would complicate or preclude accurate genotyping.  For the more highly degraded DNA samples (15-60 min 
DNase treatment), however, success rates for STR genotyping were seen to depend upon the method of DNA 
quantification.   
Panel (C) of Figure 11 shows that for amplifications based on Quantifiler
TM quantifications, a 
relatively large proportion of alleles were undetected for all of the AmpFlSTR® Identifiler
TM reporter dyes.  
As the extent of DNA fragmentation increased, the larger STR alleles for each reporter dye were the first that 
failed to reach the 100 RFU analytical threshold.  The implications for using a short qPCR target sequence 
are evident.  In these highly degraded samples, there were more 62 bp than longer STR-sized DNA 
fragments.  As a consequence, the Quantifiler
TM assay overestimated the quantity of longer template 
fragments, leading to under-amplification of the longer STR alleles and, ultimately, to inadequate quantities 
of PCR product for detection.  With this quantification method, at very high levels of degradation (45-60 
minutes of DNase treatment) less than half of the Identifiler
TM STR alleles were detected, and the 
overestimation of DNA quantity was so pronounced that even the shorter STR alleles lost significant 
intensity due to under-amplification (Figs. 11C and 12B, and Table 5). 
By contrast, quantification of these same samples using the nuTH01-mtND1 duplex qPCR method 
led to an improvement in the success rate for STR genotyping (Figure 11).  Even for the most highly 
degraded samples (60 min of DNase treatment), more than 75% of the HL60 alleles were detected.  For the 
purpose of STR genotyping highly degraded samples, these results indicate that the ~180 bp nuTH01 qPCR 
target is more appropriate for quantifying DNA than is the shorter 62 bp target.  Data provided in Table 5 
show that by basing DNA quantification on the medium-sized nuTH01 target, the intensities of the detected 
TH01 STRs were maintained at a fairly consistent level (~1800-3100 RFU/locus) despite the varying extent 
of DNA fragmentation.  Even for highly degraded samples, the short (~121 bp) D19 STRs were not over-
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amplified to the extent that they resulted in off-scale peaks, nor were the long (~293 bp) D18 STRs under-
amplified to the extent that they went undetected. 
TABLE 5 - Selected AmpFlSTR® Identifiler
TM STR intensities for DNase-degraded HL60 samples.    All 
amplifications used nominal 1 ng nuclear template amounts as quantified by nuTH01-mtND1 duplex qPCR, 
Quantifiler
TM qPCR, and slot blot hydridization.  STR intensities are provided as RFU per locus.  For 
samples exposed to DNase for 0-5 minutes, the qPCR-based STR intensities are identical because only one 
STR amplification was performed based on nearly identical quantifications of these samples by the nuTH01 
and Quantifiler
TM assays (see Figure 10).  Off-scale peaks, as identified by GeneScan® software, are 
indicated in bold.  For HL60, the average Identifiler
TM STR allele sizes for TH01, D19, and D18 are 177 bp, 
121 bp, and 293 bp, respectively (72). 
 
 
 
 
nuTH01-mtND1 Duplex qPCR 
 
Quantifiler
TM qPCR  Slot Blot Hybridization 
DNase 
Exposure 
(min) 
 
 
TH01 
(RFU) 
 
 
D19 
(RFU) 
 
 
D18 
(RFU) 
 
 
 
D19/D18 
 
 
TH01 
(RFU) 
 
D19 
(RFU) 
 
D18 
(RFU) 
 
 
D19/D18 
 
TH01 
(RFU) 
 
 
D19 
(RFU) 
 
 
D18 
(RFU) 
 
 
D19/D18 
0  1824 2809 3677  0.76  1824 2809 3677  0.76  2724 2671 4780  0.56 
1  1998 1851 2730  0.68  1998 1851 2730  0.68  2861 2360 3747  0.63 
2  2883 2489 3253  0.77  2883 2489 3253  0.77  3636 2789 3849  0.72 
3  2697 2400 3210  0.75  2697 2400 3210  0.75  3122 2465 3183  0.77 
4  2417 2043 2519  0.81  2417 2043 2519  0.81  3791 2880 2637  1.09 
5  2469 2119 3133  0.68  2469 2119 3133  0.68  2894 2469 3332  0.74 
15  2393 3434 1537  2.23  955  1472  584  2.52  6389 7053 1566  4.50 
30  3108 5156 1329  3.88  1036 1786  543  3.29  7797 9103  1766 5.15 
45 2540  5408  738 7.33 534  1153  115* --- 6563  9011  903 9.98 
60 1941  5249  473  11.10  349  825  ---  --- 5916  8845  543 16.29 
        * only one STR allele of heterozygous pair detected 
 
FIG. 12 - AmpFlSTR® Identifiler
TM VIC-
labeled STRs from DNase-degraded (45 
min) HL60 samples.  Panels show STR 
alleles for amplifications of “1 ng” amounts 
of nuclear template as determined by (A) 
nuTH01-mtND1 duplex qPCR, (B) 
Quantifiler
TM qPCR, and (C) slot blot 
hybridization.  Panel (D) is a 10-fold 
vertical scale expansion of panel (C).  
Detection and/or amplification artifacts are 
indicated as: BT = below detection 
threshold; PU = “pull-up” signal from 
adjacent detection channel; S = detected 
stutter signal; A = detected shoulder due to 
incomplete non-template nucleotide 
addition.  Full vertical-scale RFU values for 
the panels are: (A) 2500 RFU; (B) 500 
RFU; (C) 3500 RFU; (D) 350 RFU. 
 
D3 TH01  D13  D16  D2 
 
BT 
S
PU
A A
BT  BT  BT 
(A) nuTH01 
(B) Quantifiler
TM 
(C) slot blot
(D) slot blot (10x)
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STR amplifications based on slot blot quantifications resulted in very few undetected alleles, even 
for the most highly degraded samples (Fig. 11).  However, the electropherograms shown in panels (C) and 
(D) of Figure 12 indicate the presence of several artifacts due to the over-amplification of excess template 
DNA.  These artifacts include shoulder peaks due to incomplete non-template-directed nucleotide addition, 
cross-dye “pull-up” signals due to off-scale peaks in adjacent detector channels, and stutter peaks above 100 
RFU.  For some slot-blot quantified samples in the DNA degradation series, off-scale peaks led to pull-up 
signals as intense as 2700 RFU (data not shown).  Off-scale peaks are evident even for samples exposed to 
DNase for only 30 minutes (Table 5).  Inter-locus balance, as represented by the D19/D18 ratios, was 
significantly worse for the slot-blot quantified samples than for the qPCR-quantified samples (Table 5).  
Although some of these artifacts (e.g., off-scale peaks, “pull-up” signals) are possibly remedied by reducing 
CE sample injection times, other artifacts (e.g., shoulders due to incomplete nucleotide addition, poor inter-
locus balance) are repairable only by re-amplification. 
  Highly degraded samples present analytical challenges for DNA quantification and for subsequent 
STR genotyping.  The quantity and quality of DNA in such samples, which are typically comprised of 
fragments with a wide range of sizes, cannot be represented by any single qPCR assay, which is 
fundamentally biased to detect and quantify the subpopulation of fragments that are at least as long as the 
specific target sequence being amplified.  In principle, the most accurate estimate of overall DNA quantity in 
degraded samples should be provided by qPCR assays that use very short target sequences.  However, for the 
specific purpose of STR genotyping, the overall DNA quantity in a degraded sample is not necessarily the 
measurement of interest.  Our results indicate that if qPCR methods are to be used to quantify degraded DNA 
for STR genotyping, there are advantages in selecting a qPCR target sequence that is of appropriate length to 
detect those DNA fragments that are most relevant to the method of analysis.  This is particularly true for the 
highly multiplexed commercial STR genotyping kits that are used in most forensic DNA labs, kits that 
recommend the use of a fairly narrow range of template DNA to give optimal success rates for STR 
amplification and detection.  For the AmpFlSTR® Identifiler
TM STR kit, which amplifies STRs ranging from 
~100 bp to ~400 bp, our genotyping results indicate that “1 ng” quantities of highly degraded DNA are better 
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estimated by using a ~180 bp nuclear qPCR target sequence, as in the nuTH01-mtND1 duplex assay, than by 
using a 62 bp qPCR target sequence, as in the Quantifiler
TM qPCR assay.  Although this discussion is based 
on our experiments with a specific set of DNase-degraded samples, the general conclusion that the target 
length of a qPCR assay is an important consideration for quantifying DNA in degraded samples is sound.  
We are aware, however, that the degree of advantage gained by using a long target sequence for qPCR will 
likely depend on precisely how the sample is extracted and purified. 
In addition to quantifying the amount of nuclear DNA, we also used the mtND1 portion of our 
duplex qPCR assay to estimate the quantity of mitochondrial genome copies in this same set of DNase-
degraded samples.  These mtND1 quantification results are provided graphically in Figure 13. 
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FIG. 13 - Normalized quantifications of DNase-degraded HL60 samples by mtND1 (duplex) qPCR, 
Quantifiler
TM qPCR, and nuTH01 (duplex) qPCR.  Each point represents the average of duplicate 
quantifications.  For each assay, the DNA quantities are normalized relative to the measured quantity at 0 
minutes of DNase-treatment, i.e., to 8.1 ng/µL for the Quantifiler
TM assay, to 8.3 ng/µL for the nuTH01 assay, 
and to 1.3 x 10
6 mt copies/µL for the mtND1 qPCR assay.  Lines represent linear least-squares fits to early 
(0-5 min) and late (15-45 min) time points in the degradation series. 
 
In this figure, the mitochondrial quantification results shown at each time-point in the degradation series are 
normalized relative to the quantification result for the untreated sample (1.3 million mt copies/µL).  For 
comparison, the figure also shows normalized nuclear quantifications, as estimated by the nuTH01 and 
Quantifiler
TM qPCR assays for the same set of DNase-degraded samples.  Notice that the mtND1 and 
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Quantifiler
TM assays generally measured higher normalized quantities of DNA than did the nuTH01 assay.  
For example, both the mtND1 and Quantifiler
TM assays indicated that  ~25% of the initial DNA remained 
after 45 minutes of DNase exposure, while the nuTH01 assay detected only ~5% of the initial DNA 
concentration.  It is likely that because the mtND1 qPCR assay amplifies a relatively short target sequence 
(69 bp), the normalized quantifications for the mtND1 and Quantifiler
TM assays were very similar, despite 
quantifying entirely different genomes.  Because we have already seen that the selection of a short nuclear 
target has implications for STR genotyping, we were motivated to learn if the selection of a short 
mitochondrial quantification target would have a similar detrimental impact on HVI/HVII amplification 
success rates.   
To address this issue, we performed two separate sets of HVI/HVII duplex PCR amplifications on 
samples from the DNA degradation series.  In the first set, for each time-point in the series we amplified 100 
pg of nuclear DNA, as measured by the nuTH01 portion of the duplex qPCR assay.  This approach, to use 
the quantity of nuclear DNA to indirectly estimate the amount of template for HVI/HVII PCR amplifications, 
is commonly used in the forensic analysis of mitochondrial DNA, if there is sufficient nuclear DNA to be 
quantified (42, 70).  In the second set, for each time point we amplified ~14,000 mitochondrial genome 
copies, as estimated directly by the mtND1 portion of the duplex qPCR assay.  (For pristine samples of 
HL60, we had previously determined that 100 pg of nuclear DNA represented ~14,000 mitochondrial 
genome copies.)  The post-amplification yield gel results for both sets of HVI/HVII duplex PCR 
amplifications are shown in Figure 14. 
L2 L4  0    1    2    3    4   5   15  30  45  60  ON  L2 L4 
(A) Amplification of 100 pg nu DNA
opies
L2 L4  0    1   2    3    4   5   15  30  45  60  ON  L2 L4 
(B) Amplification of ~14,000 mt c
FIG. 14 - HVI/HVII post-amplification yield gel results for 
DNase-degraded HL60 samples.  Gel is EtBr stained.  Each pair 
of bands represents the HVI (~444 bp) and HVII (~416 bp) PCR 
products from 34 cycles of the duplex amplification.  Numerical 
lane designations (0 - 60) represent DNase digestion times in 
minutes; ON represents overnight DNase digestion; L2 and L4 
represent, respectively, 20 ng and 40 ng ladder bands (400 bp).  
In panel (A), amplifications used 100 pg of nuclear DNA as 
estimated by the nuTH01 portion of the duplex qPCR assay, 
except for the ON sample, which used 20 µL of digest.  In panel 
(B), amplifications used 14,000 mitochondrial genome copies as 
estimated by mtND1 portion of the duplex qPCR assay. 
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A “successful” HVI/HVII duplex PCR amplification was considered to produce sufficient quantities 
of the HVI and HVII PCR products for successful cycle sequencing.  For cycle sequencing, our laboratory 
has validated a protocol that uses the Applied Biosystems Terminator BigDye® v1.1 Cycle Sequencing 
System (42).  Although the manufacturer recommends using 3-10 ng/20 µL of PCR product in each 50 µL 
cycle-sequencing reaction (71), local validation studies indicate that successful sequencing can be routinely 
achieved even with as little as 250 pg of PCR product per reaction.  Even using the more conservative 
recommendation of 3-10 ng/20 µL, we can deduce that a “successful” HVI/HVII amplification is one that 
produces at least 0.15 ng/µL of each PCR product.  This concentration is well below the visual detection 
limit of our ethidium bromide-stained gel.  Consequently, our criterion for a successful HVI/HVII 
amplification is simply that the post-amplification yield gel shows visible evidence, even weak visible 
evidence, for two appropriately sized product bands.  Referring again to Figure 14, the visual appearance of 
two such bands for all of the amplifications indicates that both targets of the duplex qPCR assay successfully 
quantified mitochondrial DNA for HVI/HVII duplex PCR and that all amplifications produced more than 
enough of each PCR product for successful cycle sequencing.  It is, however, evident that there were 
implications for selecting a short target sequence for the mtND1 qPCR assay.  In particular, Figure 14 (panel 
(B)) shows that for highly degraded samples (15 min - overnight DNase treatment) increasingly weak 
HVI/HVII bands are seen in the post-amp yield gel.  This trend indicates that the “short” mtND1 qPCR assay 
overestimated the number of ~400 bp mitochondrial genome copies, just as the Quantifiler
TM qPCR assay 
overestimated the quantity of 100-400 bp nuclear genome copies in the same samples.  However, because the 
mitochondrial cycle sequencing protocol is capable of obtaining successful results over a very wide input 
range of PCR product (250 pg - 10 ng), these overestimations of the quantity of mitochondrial DNA by the 
mtND1 qPCR assay did not lead to any failed HVI/HVII amplifications. 
For highly degraded DNA samples, it is clear that qPCR quantification results depend upon the 
length of the amplified target sequence.  Although this dependence complicates quantification by qPCR, it 
also holds promise for providing information about the degree of DNA fragmentation in degraded samples.  
For example, in the nuTH01-mtND1 duplex qPCR assay, the relatively long nuclear target sequence makes 
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quantification of the nuclear genome more sensitive to the degree of fragmentation than quantification based 
on the shorter mitochondrial target sequence.  This difference in sensitivity makes it possible to relate the 
degree of DNA fragmentation in a sample to the empirical ratio of mitochondrial genome copies to nuclear 
genome copies (mt#:nu#) as determined by the nuTH01-mtND1 duplex qPCR assay.  Specific examples of 
this relationship are seen in the STR and qPCR data obtained from the HL60 DNase-degradation series.  For 
the non-degraded HL60 sample, the mt#:nu# was ~530, as estimated from the duplex qPCR assay, and the 
degree of fragmentation was low, as expected and as deduced from the low D19/D18 STR intensity ratio of 
0.76 (Table 5).  For moderately degraded HL60 samples (1-5 min DNase treatment), the qPCR-based 
mt#:nu# ratios remained fairly constant, varying between ~390 to ~510, as did the corresponding D19/D18 
STR intensity ratios, varying between 0.68 to 0.81 (Table 5).  However, for the more highly degraded HL60 
samples, the qPCR-based mt#:nu# ratios increased dramatically and systematically (1400 for 15 min, 1700 
for 30 min, 2600 for 45 min, 3700 for 60 min DNase treatment) in direct correspondence with increasing 
D19/D18 STR intensity ratios (from 2.23 to 11.10, Table 5).  These related trends suggest that if one were to 
determine an empirical mt#:nu# ratio for an HL60 sample of unknown quality, it would be possible to use 
this ratio to infer an approximate degree of DNA fragmentation in that sample.  Of course, the extension of 
such an approach to estimate the degree of DNA fragmentation for the variety of sample and tissue types 
encountered in real forensic samples would require empirical knowledge of the mt#:nu# ratios for purified 
extracts from the corresponding non-degraded samples and tissues. 
  
nuTH01-mtND1 Duplex qPCR Validation:  Reference and Casework-type Samples 
In order to further evaluate the nuTH01-mtND1 duplex qPCR assay, we quantified DNA extracts 
from a variety of reference and simulated casework samples for subsequent STR genotyping and 
mitochondrial HVI/HVII amplifications.  A summary of results for a subset of 40 samples from this study is 
presented in Table 6.  For STR genotyping, each amplification used 1 ng of nuclear template DNA as 
determined by the nuTH01 portion of the duplex qPCR assay.  STR results are represented in the table by the 
RFU values per locus for three of the 15 AmpFlSTR® Identifiler
TM STR loci, TH01(163-202 bp), D19(102-
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TABLE 6 - Summary of nuTH01-mtND1 qPCR quantification results for selected reference and casework-type samples.  Where indicated, NSF and 
SF represent, respectively, the non-sperm fraction and sperm fraction from a differential extraction protocol.  All quantification results, qPCR and 
slot blot, are from single replicate experiments.  IS indicates that insufficient sample was available for amplification.   
Identifiler
TM STR Data (RFUs per locus) 
 
 
 
Sample Number and Description 
 
 
nuTH01 
qPCR 
(ng/4 µL) 
 
 
 
 
Slot Blot 
(ng/4 µL) 
 
 
 
 
mtND1 qPCR 
(1000 copies/4 µL) 
 
 
Genome Copy 
Ratio - 
Mitochondrial: 
Nuclear 
 
 
Mitochondrial 
HVI/HVII Post-
Amplification 
Yield Gel 
 
TH01 
 
D19 
 
D18 
 
D19/D18 
 
 
Approximate 
Mitochondrial 
Copies Amp’ed 
for Limited Samples 
 
1                     
                       
                     
                   
                       
                     
                   
                   
                       
                       
                   
                   
                       
                     
liquid  blood 0.42 0.60 200 1600 +/- 1213 5199  255 20.4
2 liquid  blood 1.22 0.95 380 1000 + 1349 1065 980 1.1
3  dried blood on black sateen  19.0  11.6  1400  240  +  1814  1444  1403  1.0   
4  dried blood in potting mix  3.86  9.11  480  410  +  7829  6079  1033  5.9   
5  dried blood on newspaper  0.51  0.45  60  390  +  2522  1586  1363  1.2   
6  dried blood on denim  0.12  0.10  37  1000  +  4486  3562  775  4.6   
7  dried blood on wool  2.25  1.50  300  440  +  2096  1335  1230  1.1   
8  dried blood on carpet  0.46  0.39  86  620  +  2747  2204  1429  1.5   
9  dried blood on leather  0.15  0.10  18  400  +  2562  1468  1292  1.1   
10  dried blood on toothpick 
 
1.48  0.66  290  650  +  2466  1399  1145  1.2   
11 femur  (powdered) 0.24 0.05 170 2300 + 2412 3231 378 8.6
12  non-root hair shaft (Chelex)  0  0  9.1  -  +  IS  IS  IS  IS   
13  non-root hair shaft (DNA-IQ) 
 
0  0  2.0  -  +/-  IS  IS  IS  IS  5000 
  14 toenail 4.83 0.88 9700 6600 + 2319 3038 459 6.6
15 toenail 1.06 0.22 1400 4400 + 1810 1523 333 4.6
16  semen on denim (NSF)  0.53  0.13  50  320  +  3459  2335  1323  1.8   
17  semen on boxer shorts (NSF)  0.23  0.09  990  14000  +/-  2867  4702  456  10.3   
18  vaginal swab (NSF)  32.1  19.9  880  90  +  3046  1869  927  2.0   
19  electric razor shavings  1.83  0.80  2900  5200  +/-  1661  1920  484  4.0   
20  swab of razor  0.42  0.07  210  1700 
 
+  1218  915  534  1.7   
21 bloody  bandage 52.4 10.1 1700 110 + 1747 1319 1055 1.3
21  saliva from cigarette butt  0.77  0.29  470  2000  +  1814  1553  671  2.3   
22  saliva from envelope 
 
0.52  0.35  160  1000 
 
+  1890  1308  847  1.5   
24 toothbrush 1.85 1.06 390 700 + 1608 1314 749 1.8
25  saliva from coffee cup 
 
0.84  0.29  270  1100 
 
+  3017  2051  936  2.2   
26 buccal  swab 16.0 5.10 4800 990 + 1677 1182 1130 1.0
27 buccal  swab 17.8 6.70 4900 910 + 1722 1476 937 1.6
28 buccal  swab 5.49 2.13 2400 1400 + 2059 1335 1134 1.2
29  saliva from envelope  0.04  0  3.4  280  +/-  IS  IS  IS  IS  1300 
30  vaginal swab (SF)  0.04  0  0.036  2.7  0  1204  1417  1005  1.4  300 
31  vaginal swab (SF)  4.68  2.99  0.71  0.5  +  2464  1555  1101  1.4   
32  semen on denim (SF)  2.03  1.61  0.014  0.02  +  1580  1067  1038  1.0  700 
33  semen on leather (SF)  0.27  0.09  0  0  +  3579  2635  1888  1.4  (20 µL) 
34  semen on cotton fabric (SF)  39.4  28.5  0.16  0.01  +  2164  1592  1272  1.3  7000 
35  semen/blood on swab (SF)  0.74  1.06  0.046  0.2  +  1857  1832  1304  1.4  2300 
36  semen on boxer shorts (SF) 
 
0.40  0.15  38  310  +/-  3963  3068 
 
552  5.6   
37 muscle  tissue
 
133 31.4 20000
 
500 + 1323 620 696 0.9
38 baby  tooth 0.26 0.23 38 480 +/- 2017 1846 1354 1.4
39 baby  tooth
 
10.6 2.19 800 250 + 2432 1780 1052 1.7
40 tooth 53.1 34.1 5300 330 + 1723 1197 1198 1.0
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136 bp), and D18(262-346 bp) (72).  Data for these particular loci were selected because their amplicons represent 
intermediate, short, and long STR alleles, respectively, in the genotyping kit.  The D19/D18 RFU ratios are 
tabulated to provide a simple STR-based metric to indicate DNA degradation.  For HVI/HVII amplifications, 
~14,000 mitochondrial copies were used per reaction, as quantified by the mtND1 portion of the duplex qPCR 
assay.  For some samples, limited quantities required amplification of fewer than 14,000 copies (last column in 
the table).  HVI/HVII amplifications were evaluated by post-amplification gel electrophoresis, where the gel 
results are represented by either a “+” (to indicate two visible HVI/HVII product bands with expected intensities), 
a “+/-“ (to indicate two visible product bands with lower than expected intensities), or a “0” (to indicate that no 
product bands were seen).  Both “+” and “+/-“ results indicate that the amplifications provided more than enough 
HVI/HVII product for cycle sequencing. 
  For nearly all of these casework-type samples, quantifications provided by the nuTH01-mtND1 duplex 
qPCR assay led to successful STR and HVI/HVII amplifications.  With one exception, each sample that contained 
a sufficient quantity of nuclear DNA was amplified to give a full STR profile.  For the single exception, sample 
#1, only the CSF alleles were undetected, a result consistent with the very high degree of DNA degradation 
evident in this sample (D19/D18 > 20).  Sample #4 was inhibited, as indicated by nuTH01 and mtND1 qPCR 
amplification curves with shallow slopes and reduced final plateau values (data not shown).  Due to the presence 
of co-extracted inhibitors in this sample, the nuTH01 qPCR assay underestimated the quantity of nuclear DNA, 
leading to STR amplification of excess template and to unusually intense TH01 and D19 allele signals.  Sample 
#30 gave an unsuccessful HVI/HVII duplex amplification; this sample was extracted from a sperm cell fraction 
that contained very little nuclear or mitochondrial DNA.  Several other sperm cell extracts (samples 31-35) gave 
successful HVI/HVII duplex amplifications despite having very low or even undetected quantities of 
mitochondrial DNA, indicating that the mtND1 portion of the assay significantly underestimated the 
mitochondrial quantity in these particular samples.  As discussed earlier in this paper, such underestimations of 
DNA by the mtND1 qPCR assay are expected when the ratio of mitochondrial to nuclear genome copies is low, 
as is the case for these sperm fraction samples.  Finally, the empirical ratio of mitochondrial genome copies to 
nuclear copies (mt#:nu#) spanned a wide range (<1 to 14,000) for the various types of DNA extracts.  Depending 
upon sample type, degraded STR patterns (D19/D18 > ~4) were seen at mt#:nu# ratios ranging from 310 to 
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14,000.  It is significant that for any sample exhibiting a mt#:nu# ratio greater than 2000, there was corresponding 
evidence for DNA degradation in the STR intensity ratios.  This correspondence is consistent with our previous 
discussion of mt#:nu# ratios for the DNase-degraded samples and suggests that the genome copy number ratios 
estimated from the duplex qPCR assay can provide useful information about DNA quality. 
 
Conclusions 
We have developed a duplex qPCR assay for the specific quantification of human nuclear and 
mitochondrial genomes in a variety of forensic-type samples.  The nuclear portion of the assay (nuTH01) 
quantifies DNA in samples with concentrations ranging from ~10 pg/µL to at least 25 ng/µL, while the 
mitochondrial portion of the assay (mtND1) provides quantifications over the range ~4 copies/µL to ~2 million 
copies/µL.  The quantifications were suitably accurate and precise for determining template quantities for nuclear 
STR genotyping and mitochondrial HVI/HVII sequencing applications. 
For quantifying DNA in highly degraded samples, our results indicate that the length of the qPCR target 
sequence is an important consideration when selecting an assay for forensic use.  For the purpose of STR 
genotyping, the nuTH01 portion of the duplex qPCR assay, which uses a ~170-190 bp target sequence, was found 
to be well suited for estimating nuclear DNA quantities in highly degraded samples.  Because this assay detects 
and quantifies DNA fragments that are of the same general length as the STR alleles amplified in commercial 
genotyping kits, it provided an optimal estimate of the quantity of nuclear template to amplify for successful STR 
genotyping.  By contrast, less than optimal results were obtained when these same highly degraded samples were 
quantified using a nuclear qPCR assay with a much shorter target sequence (62 bp).  This assay, by detecting 
shorter DNA fragments, overestimated the quantity of STR-sized fragments, resulting in a relatively high 
proportion of under-amplified and undetected STR alleles.  Slot blot quantifications of the same highly degraded 
samples resulted in dramatically underestimated quantities of nuclear DNA, leading to over-amplification of 
excess template, off-scale STR peaks, and undesired artifact signals.   
Because the nuTH01-mtND1 duplex qPCR assay utilizes a long target sequence for detection of the 
nuclear genome and a short (69 bp) target for mitochondrial detection, the empirical mitochondrial-to-nuclear 
genome copy number ratio was seen to depend upon the degree of DNA fragmentation of the sample.  In a 
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controlled DNase-degradation series, this copy number ratio was seen to vary from ~530 for intact DNA to ~3700 
for highly degraded DNA.  For these samples and generally for casework-type samples, increased mitochondrial-
to-nuclear genome copy number ratios were correlated with increased occurrences of degraded STR patterns (i.e., 
size-dependent imbalances in STR allele intensities). 
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(ii) A qPCR Assay for the Assessment of DNA Degradation in Forensic Samples 
Introduction 
 
Short tandem repeat (STR) genotyping, due to its high power of discrimination for human identification, 
is typically the analytical method of first choice for forensic applications.  The poor quality and/or quantity of 
extracted nuclear DNA in samples of forensic interest, however, often preclude successful STR genotyping, 
resulting in partial or unsuccessful STR profiles.  The successful analysis of such samples could benefit from 
methods that would not only assess the quantity of DNA, but also the presence and degree of DNA degradation.  
Reynolds et al. (73), for example, have suggested that DNA degradation could be assessed by PCR amplification 
and detection of two DNA target sequences of different lengths.  This approach has been used by Alonso et al. 
(38) who have developed two singleplex qPCR assays to separately quantify short and long mitochondrial target 
sequences to assess degradation in forensic samples.  As part of our previous development and validation of a 
duplex qPCR assay for quantifying nuclear and mitochondrial DNA (9 and previous section in this report), we 
have also shown that for highly degraded samples the quantity of DNA depends significantly on the length of the 
target sequence that is amplified in the assay.  For highly fragmented DNA samples, a qPCR assay that amplified 
a 62 bp target sequence detected more DNA than a qPCR assay that amplified a ~170-190 bp target, a result 
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consistent with the allele-length-dependent STR intensity profiles that are commonly seen for degraded DNA 
(34).  In this report, we describe a real-time qPCR assay for the simultaneous quantification of two different target 
lengths of human nuclear DNA, an assay which determines if, and to what degree, the DNA is degraded.  In 
addition, the inclusion of a third amplification target, a synthetic oligonucleotide, provides an internal PCR 
control (IPC) that allows for the assessment of PCR inhibition.  This assay was designed to be of general utility 
for forensic DNA quantifications, but to be particularly useful for the post-extraction analysis of samples that 
contain highly degraded DNA.  Such samples, though not uncommon in standard casework, are often encountered 
in instances of mass disasters, mass graves, and missing persons’ cases (34,35).   
Materials and Methods 
qPCR Assay Design  
  Primers and probes for the nuTH01-nuCSF-IPC triplex TaqMan® qPCR assay (Table 7) were designed 
using Applied Biosystems’ PrimerExpress™ v2.0 software with the exception of the nuCSF forward primer 
(nuCSF-F) which was designed with Primer3 (74).  DNA sequences for design work were downloaded from the 
STRBase (45) website and the GenBank resource at the National Center for Biotechnology Information (NCBI) 
website (44).   
TABLE 7 - Oligonucleotide sequences for nuTH01 primers and probe, nuCSF primers and probe and IPC 
primers, probe, and single-stranded oligonucleotide template. 
______________________________________________________________________________   
 
Oligonucleotide    Sequence                                                                                             
______________________________________________________________________________ 
 
nuTH01-F     5' - AGG GTA TCT GGG CTC TGG - 3' 
nuTH01-R     5' - GGC TGA AAA GCT CCC GAT TAT - 3' 
nuTH01-probe     5' - FAM-ATT CCC ATT GGC CTG TTC CTC CCT T-BHQ - 3' 
nuCSF-F      5'- GGG CAG TGT TCC AAC CTG AG - 3' 
nuCSF-R      5'- GAA AAC TGA GAC ACA GGG TGG TTA - 3' 
nuCSF-probe      5'- VIC-CAA CCT GCT AGT CCT T-MGB-NFQ - 3' 
IPC-F        5'- AAG CGT GAT ATT GCT CTT TCG TAT AG - 3' 
IPC-R        5'- ACA TAG CGA CAG ATT ACA ACA TTA GTA TTG - 3' 
IPC-probe      5'- NED-TAC CAT GGC AAT GCT-MGB-NFQ  - 3' 
IPC-oligo      5'- AAG CGT GAT ATT GCT CTT TCG TAT AGT TAC CAT  
   GGC AAT GCT TAG AAC AAT ACT AAT GTT GTA ATC  
   TGT CGC TAT GT - 3' 
______________________________________________________________________________
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The nuTH01 assay is as previously described in the preceding section (i) of this report.  In brief, it 
spans the STR sequence at the human tyrosine hydroxylase (TH01) gene on chromosome 11 (11p15.5), has 
an amplicon length of ~170-190 bp, and utilizes a FAM-labeled hydrolysis probe for detection.  The nuCSF 
assay targets an intron region of the human c-fms proto-oncogene for the CSF-1 receptor gene on 
chromosome 5 (5q33.3-34).  This target, located in the flanking region of the CSF1PO STR locus, was 
selected for its specificity for higher primates as indicated by sequence homology investigations.  The nuCSF 
assay produces a 67 bp amplicon and utilizes a VIC-labeled TaqManMGB® probe for detection.  The IPC 
(internal PCR control) assay targets a 77 bp synthetic single-stranded oligonucleotide that was designed to 
avoid homologies to sequences found in the NCBI GenBank database.  The IPC assay was designed with a 
NED-labeled TaqManMGB® probe for use in this triplex format. 
  Prior to ordering any synthetic oligonucleotides, the Basic Local Alignment Search Tool (BLASTn) 
(50) on the NCBI website was used to compare potential primer and probe sequences to all available DNA 
sequences to avoid inadvertent homology to non-target sequences and identify possible occurrences of cross-
species reactivity.  Known single nucleotide polymorphisms (SNPs) were also avoided by obtaining SNP 
information from the NCBI SNPdB website (51) and the On-Line Mendelian Inheritance in Man (OMIM) 
website (52).  Once developed, singleplex, duplex and triplex qPCR assays were optimized based on 
published recommendations (53,54). 
 
 Standards and Samples 
Pre-quantified, high molecular weight human genomic female DNA (#G1521) purchased from 
Promega (Madison, WI) was used as the quantification standard for all experiments.  Human DNA extracts 
for these experiments consisted of pre-quantified HL60 DNA (ATCC, Manassas, VA) and TaqMan® 
Control Human Genomic DNA (Applied Biosystems, Foster City, CA) and various reference, non-probative 
and simulated casework sample extracts generated in our laboratory.  All of the casework-type samples were 
extracted using an organic extraction protocol consisting of ProK/SDS digestion, phenol/chloroform 
extraction and Centricon100 (Millipore, Bedford, MA) concentration into Tris-EDTA buffer (TE
-4) (most 
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samples) or differential extractions of sperm and epithelial fractions using a DTT-based digestion protocol 
(39) (simulated sexual assault samples).  Pre-quantified, non-human genomic DNA extracts were purchased 
from various vendors: E. coli, C. perfringens (Sigma, St. Louis, MO), B. subtilis, S. epidermidis, C. albicans 
(ATCC), mouse (Promega) and cat, chicken, cow, dog, fish, horse, monkey, pig, and rat (Zyagen Labs, San 
Diego, CA).  All extracts were stored at -20 ºC. 
To study the effects of inhibition on the nuTH01-nuCSF-IPC assay, porcine hematin from Sigma 
(#H3281) was chosen for use as an inhibitor.  Twenty-five milligrams of solid hematin were dissolved in 1 
mL of 1 N NaOH.  The resulting solution was diluted to 39.5 mL with sterile water to produce a 1 mM 
hematin solution.  Separate tubes, each containing 40 ng of TaqMan® Control Human Genomic DNA, were 
treated with increasing volumes of 1 mM hematin and brought to a total volume of 40 µL with sterile water.  
The final hematin concentrations ranged from 0 µM (0 µL of 1 mM hematin) to 800 µM (32 µL of 1 mM 
hematin).  In order to control for the possible inhibitory effect of NaOH on the PCR reaction, a separate tube 
received 40 ng of DNA, 0 µL of hematin, 4 µL of 0.2 N NaOH and sterile water to a final volume of 40 µL.  
The final NaOH concentration in this tube was the same as in the tube with the greatest concentration of 
hematin (800 µM). 
A degradation series was prepared by digesting high molecular weight HL60 DNA with DNase I 
(Invitrogen, Carlsbad, CA) for progressive lengths of time.  A reaction containing 15.7 µg DNA, 10x DNase 
I Reaction Buffer and sterile water to bring the reaction volume to 110 µL was prepared, 10 µL was 
removed, and 2.5 µL DNase I (1 U/µL) was added.  A degradation series was achieved by incubating the 
reaction at room temperature (24 ºC), removing 10 µL volumes at 2.5, 5, 10, 15, 20, 25, 40, 60, 90 and 180 
minute time points, and stopping DNase activity by mixing the DNA with 2 µL of 25 mM EDTA and heating 
at 65 ºC for 15 min.  Although the 0 min sample contained no DNase, this sample was “stopped” in the same 
manner as all other samples.  DNA fragmentation was assessed by gel electrophoresis (2% agarose, ethidium 
bromide detection) using the DNA molecular weight size marker XIV (Roche Applied Science, Indianapolis, 
IN).  Four microliters of a 1:120 dilution of each degraded sample was assayed via qPCR. 
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 nuTH01-nuCSF-IPC Triplex qPCR Quantifications 
Primer and probe sequences for the nuTH01-nuCSF-IPC triplex qPCR assay are displayed in Table 
7.  The optimized triplex assay was run in a 20 µL reaction volume that included 10 µL of 2X TaqMan® 
Universal Master Mix, no UNG (Applied Biosystems), 0.5 µL of 5 U/µL AmpliTaq Gold® enzyme, 1 µL of 
3.2 µg/µL non-acetylated BSA (Sigma) and 4 µL of sample.  Primers, probes and IPC oligo were added at 
the following concentrations: 600 nM each nuTH01 primer; 200 nM nuTH01-probe; 400 nM each nuCSF 
primer; 100 nM nuCSF-probe; 100 nM each IPC primer; 100 nM IPC-probe; 90,000 copies IPC-oligo.  
Primers and the probe for the nuTH01 assay and the IPC primers and oligo were purchased from Qiagen-
Operon (Alameda, CA).  The IPC and nuCSF probes and both nuCSF primers were purchased from Applied 
Biosystems.  Primer stocks were made in sterile, de-ionized water while probe stocks were made in TE
-4.  
Developmental singleplex, duplex and triplex assays were run using the same reagents as described above, 
although concentrations were altered for optimization experiments and, unless otherwise indicated, additional 
AmpliTaq Gold® enzyme was not included in the reaction.  In these cases, the remaining volume was made 
up with TE
-4.   
An Applied Biosystems Prism® 7000 SDS instrument and ABI Prism® 7000 SDS Software version 
1.1 were used to collect real-time qPCR data.  The instrument was configured for the following run 
conditions: 20 µL sample volumes; 9600 emulation mode; one 10 minute 95 ºC polymerase activation step, 
followed by 45 cycles of 2-step qPCR (15 s of 95 ºC denaturation, 60 s of 60 ºC combined anneal/extension).  
A ROX-labeled passive reference oligonucleotide (included in the Applied Biosystems qPCR Master Mix) 
was employed to correct for well-to-well variations in background fluorescence.  
Amplification curves were analyzed using the automatic baseline feature of the version 1.1 ABI 
Prism® 7000 SDS software (except the IPC portion of the nuTH01-nuCSF-IPC assay in the inhibition 
experiment which was analyzed using a manual baseline set between cycles 6 and 20) and a different 
empirically established threshold for each assay (nuTH01 threshold = 0.15; nuCSF threshold = 0.05; IPC 
threshold = 0.025).  For some developmental optimization experiments an IPC cycle threshold of 0.05 was 
used.  For each experiment, the 7000 SDS software used amplification results from a freshly prepared 
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dilution series of standard DNA to generate two calibration curves (one for nuTH01 and one for nuCSF) by 
plotting CT (cycle threshold) vs. log C0 (initial standard DNA concentration).  DNA quantifications for 
unknown samples were interpolated from the resulting linear calibration curves.  These calibration and 
interpolation steps are semi-automatic features of the 7000 SDS software.  For both the nuTH01 and nuCSF 
assays, calibration plots were constructed using data from duplicate samples containing 32, 3.2 and 0.32 ng 
of Promega human genomic female standard DNA and triplicate samples containing 0.032 ng.  One TE
-4 
negative control was included in each run.  All efficiency calculations were determined using the slopes of 
the calibration curves in the following formula (56): % PCR efficiency = (10
(-1/slope) - 1)*100.  
 
STR Genotyping 
STR genotyping was performed using the AmpFlSTR® Identifiler
™ PCR Amplification kit from 
Applied Biosystems.  Amplifications were typically performed using 1 ng of template DNA, as 
recommended by the manufacturer, although 2 and 4 ng of template were used for some studies.  Twenty-
five microliter amplifications were performed in an ABI GeneAmp® 9700 PCR thermocycler and STRs 
were resolved and detected on an ABI Prism® 3100 Genetic Analyzer, according to the manufacturer’s 
instructions.  Samples were injected for 3, 5 or 10 sec depending upon the goal of the experiment.  Data were 
analyzed at a minimum threshold of 100 RFU and a baseline of 35 using GeneScan® (v.3.7.1/NT) and 
Genotyper® (v.3.7/NT) from Applied Biosystems.  
 
Results and Discussion 
Development of the nuTH01-nuCSF Duplex qPCR Assay 
A multiplex qPCR assay to assess DNA degradation relies on the simultaneous quantification of long 
and short target sequences in the same genome.  For the long target sequence, we selected the nuTH01 qPCR 
assay (170-190 bp) developed for a previously described nuclear-mitochondrial duplex qPCR assay (9).  This 
target, though not as long as the largest STR amplicons produced by commercial genotyping kits, is roughly 
in the middle of the range of STR amplicons and was previously found to accurately predict DNA 
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quantifications for STR genotyping applications (9).  Furthermore, the 170-190 bp length is not large enough 
to overly compromise the TaqMan® PCR efficiency.  For the short target sequence (<70 bp), several 
candidate assays were designed and tested at primate-specific nuclear target sequences.  One assay, 
designated here as nuCSF, possessed the best qPCR properties, e.g., lowest cycle threshold (CT) values, 
lowest variance in CT, optimal PCR efficiency, and optimal final fluorescence signals (∆Rn, the normalized, 
baseline-corrected qPCR fluorescence).  This assay, which amplifies a 67 bp target sequence located ~40 bp 
upstream of the (AGAT)n repeats at the CODIS CSF1PO STR locus, was selected for further work. 
The nuTH01 and nuCSF qPCR assays were tested on both non-degraded and highly degraded DNA 
samples to ensure that equivalent results would be obtained in both singleplex and in duplex reactions.  For 
these experiments, four HL60 samples from an existing DNaseI degradation series were used as template.  
These samples exhibited significantly different degrees of degradation because of varied exposure to DNase I 
(0 min, 5 min, 20 min, 60 min).  Gel electrophoresis results (Figure 9) indicated that the 0 min sample 
consisted of high molecular weight DNA, while the average fragment length was >2000 bp for the 5 min 
sample, ~400 bp for the 20 min sample and ~100 bp for the 60 min sample.  Given these differences in 
average DNA fragment size, we expected that the empirical ratio of the quantity of short nuCSF amplicons to 
the quantity of long nuTH01 amplicons would provide a useful estimation of the degree of DNA degradation 
present in each sample.  Throughout the remainder of this paper, this ratio of nuCSF to nuTH01 
quantification will be referred to as the “qPCR degradation ratio.”  An initial experiment showed that nearly 
equivalent quantifications could be obtained by running the nuTH01 and nuCSF qPCR assays in singleplex 
and duplex (Table 8 – Expt. 1).  Although there was a slight decrease in efficiency in the duplex qPCR 
assays, the degradations ratios for the singleplex and duplex assays were in very good agreement. 
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TABLE 8 - Summary of assay conditions and results from four key optimization experiments for the nuTH01-nuCSF-IPC triplex qPCR assay.  
   qPCR Degradation Ratio 
in Degraded Samples 
  
 
Forward Primer/Reverse Primer/Probe ** 
(nuTH01 assay, nuCSF assay, IPC assay) 
 
Extra 
Taq? 
 
nuTH01 
Efficiency 
 
nuCSF 
Efficiency  0 min  5 min  20 min  60 min 
Expt. 1  nuTH01 singleplex*  600/600/200  no  92%  -  1.0  1.5  4.0  17.0 
 nuCSF  singleplex*               
                   
400/400/100 no - 93%
nuTH01-nuCSF  duplex 600/600/200,  400/400/100 no 89% 88% 1.3 1.5 3.7 15.4
Expt. 2  nuTH01-nuCSF duplex  600/600/200, 400/400/100  no  94%  94%  0.9  1.4  3.9  21.3 
  nuTH01-nuCSF-IPC triplex  600/600/200, 400/400/100, 50/50/200  no  93%  97%  1.1  1.9  4.4  54.9 
Expt. 3  nuTH01-nuCSF duplex  500/500/200, 300/300/200  no  84%  83%  1.0  1.4  3.5  15.5 
  nuTH01-nuCSF duplex  500/500/200, 300/300/200  2.5 U  86%  83%  1.0  1.6  3.2  10.3 
  nuTH01-nuCSF-IPC triplex  500/500/200, 300/300/200, 100/100/100  no  70%  92%  1.0  1.2  3.1  27.1 
  nuTH01-nuCSF-IPC triplex  500/500/200, 300/300/200, 100/100/100  2.5 U  91%  96%  1.2  1.4  3.4  10.4 
Expt. 4  nuTH01-nuCSF duplex  600/600/200, 400/400/100  no  89%  88%  1.0  1.2  3.0  15.1 
  nuTH01-nuCSF duplex  600/600/200, 400/400/100  2.5 U  87%  96%  1.1  1.2  3.2  13.4 
  nuTH01-nuCSF-IPC triplex  600/600/200, 400/400/100, 100/100/100  no  87%  86%  0.8  1.6  4.4  243.4 
  nuTH01-nuCSF-IPC triplex  600/600/200, 400/400/100, 100/100/100  2.5 U  95%  100%  0.9  1.3  3.0  21.8 
* Singleplex qPCR degradation ratios were determined by combining the data from the nuCSF and nuTH01 singleplex assays. 
** Values indicate nM concentrations of primers and probes for each of the three assays within the triplex. 
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Development and Optimization of the nuTH01-nuCSF-IPC Triplex qPCR Assay 
   As the next step, an IPC assay for detecting the presence of co-extracted PCR inhibitors was added 
to the duplex nuTH01-nuCSF assay.  An IPC assay is especially useful for samples that are inhibited to such 
an extent that no amplification is detected above baseline.  For such samples, an IPC assay can differentiate 
null amplifications due to inhibition from those simply due to insufficient quantities of template DNA.   For 
our IPC assay, we designed a TaqManMGB® assay utilizing a 77 bp artificial target sequence (Table 7 – 
“IPC-oligo”).  Using the BLASTn tool to search the GenBank database, this artificial target sequence was 
custom designed so that the primer binding regions would be specific to the target and would avoid spurious 
amplifications of human and non-human genomic DNA.  Real-time qPCR experiments using the IPC primers 
(900 nM IPC-F and IPC-R) with SYBR Green detection gave null amplifications for up to 64 ng of human 
female DNA (results not shown).  Based on these null amplifications and on the lack of significant 
homologies to GenBank sequences, the IPC was determined to be suitably specific for forensic use.  For the 
purpose of developing a triplex qPCR assay, the TaqManMGB® probe for the IPC was labeled with NED.  
Although the NED detection channel is significantly less sensitive than either the FAM or VIC channels on 
the ABI Prism® 7000 SDS instrument, it was the sole channel available for triplex detection as the ROX 
channel was used for normalization to a passive reference dye.  Consequently, the signal-to-noise ratios for 
the IPC assay were sub-optimal, a situation that would likely improve if the assay were run on an instrument 
optimized for NED detection (e.g., the ABI 7500 (75,76)) or if a detection channel capable of improved 
spectral separation (e.g., for Cy5) were available.  A singleplex TaqManMGB® IPC assay performed on 1 
ng of genomic DNA from human and 15 non-human species confirmed that the IPC assay did not amplify 
any of the examined species (results not shown).   
  An initial attempt at a triplex qPCR assay combined the IPC assay (including 90,000 copies of IPC-
oligo template) with the initial nuTH01-nuCSF duplex (Table 8 – Expt. 2).  Primer-limiting conditions were 
utilized for the IPC assay to minimize the effect of adding this third reaction to the PCR amplification.  Most 
samples gave nearly equivalent degradation ratios in duplex and triplex.  For the most highly degraded DNA 
sample, however, there was an artificially high degradation ratio (54.9 for the triplex assay vs. 21.3 for 
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duplex) due to a delayed CT for the nuTH01 assay in triplex.  The nuTH01 assay, which was the last to cross 
the amplification threshold in triplex, likely experienced a reduced PCR efficiency due to the earlier nuCSF 
and IPC amplifications.  The signal strength (∆Rn) of the IPC assay was also significantly reduced in the 
triplex assay (compare Figures 15a and 15b).  Based on these results, it was apparent that it would be 
necessary to optimize PCR conditions for the triplex assay, both to ensure accurate nuTH01 quantifications 
for highly degraded samples and to improve the IPC amplification. 
  Several approaches were taken to optimize the triplex assay.  First, in order to improve the IPC 
signal, we increased the primer concentrations and lowered the probe concentration relative to those initially 
used in the triplex assay.  Second, the primer and probe concentrations for the nuTH01 and nuCSF assays 
were modified, mainly in an attempt to limit the nuCSF PCR so that it would not reduce the efficiency of the 
nuTH01 PCR in degraded samples.  This modification alone was unsuccessful.   In this triplex, for example, 
the PCR efficiency of the nuTH01 assay (70%) was significantly lower than that of the nuCSF assay (92%) 
(Table 8 – Expt. 3).  As a final approach, additional AmpliTaq Gold® polymerase (2.5 U/20 µL reaction) 
was used to augment the ABI Universal Master Mix, a common tactic for increasing efficiencies in multiplex 
qPCR assays (77).  The additional enzyme in the triplex reactions led to improved PCR efficiencies for both 
the nuCSF and nuTH01 assays as well as to more accurate degradation ratios for highly degraded DNA.  The 
additional polymerase also improved the signal strength of the IPC assay (compare Figures 15c and 15d).  
Based on the slightly higher PCR efficiencies obtained in Experiment 4 relative to Experiment 3 (Table 8), 
the PCR conditions of Experiment 4 were selected for the triplex qPCR assay.  As a final optimization step, 
we titrated the triplex assay with polymerase (0, 1, 2, and 2.5 additional U per 20 µL reaction) and found that 
at least 2 U of additional AmpliTaq Gold® polymerase were needed to achieve efficient PCR for all assays 
in the triplex (results not shown).
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FIG 15 - Developmental IPC amplification curves.  Comparisons of (a) and (b) show that the signal strength (∆Rn) was significantly reduced in the 
triplex assay and of c) and d) show that adding extra Taq enzyme improved signal strength.
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Species Specificity of the nuTH01-nuCSF-IPC Triplex qPCR Assay 
Although no cross-reactivity to non-human DNA was observed for any of the singleplex assays 
individually, it was important to assess species specificity of the nuTH01-nuCSF-IPC triplex qPCR 
amplification.  To do this, the triplex assay was run using 1 ng of template DNA in duplicate from each of 
fifteen different non-human species.  No cross-reactivity to non-human DNA was observed.  These results 
indicate that the nuTH01-nuCSF-IPC triplex qPCR assay is sufficiently specific for forensic applications.  
Although the tests did not include DNA from higher primates, based on previous work at the TH01 and 
CSF1PO STR loci (61,62) we anticipate that the nuTH01-nuCSF-IPC triplex qPCR assay would amplify 
and detect such samples.  Sequence homology (NCBI GenBank BLASTn) investigations do not, 
however, indicate significant homologies to non-human DNA sequences for the nuCSF primer pair. 
 
Detection of DNA Degradation with the nuTH01-nuCSF-IPC Triplex qPCR Assay  
The premise for a degradation qPCR assay is that, due to the availability of fewer target 
sequences of sufficient length for amplification in degraded samples, an assay requiring a longer target 
template should be more sensitive to degradation than an assay requiring a shorter target template.  In 
developing and optimizing the nuTH01-nuCSF-IPC triplex assay, we indeed demonstrated this difference 
in sensitivity.  That is, for the small set of DNase-degraded samples that were used in development and 
optimization, the empirical ratio of shorter (67 bp nuCSF) to longer (170-190 bp nuTH01) target 
sequences was seen to be closely related to the extent of DNA degradation.  Although this qPCR 
degradation ratio appeared to be a good empirical tool for diagnosing DNA fragmentation, it was also 
important to determine if this ratio would be useful for predicting the success of future STR analysis.   
To assess the ability of the nuTH01-nuCSF-IPC triplex assay to quantify DNA in degraded 
samples, a 10-point degradation series was prepared by treating aliquots of high molecular weight 
genomic DNA (HL60) with DNase I for increasing periods of time ranging from 2.5 to 180 minutes.  The 
result was a degradation series exhibiting incremental increases in the extent of DNA fragmentation 
(Figure 16).   
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FIG. 16 - HL60 DNase I degradation series (EtBr-stained).  Times indicate lengths of DNase I treatment.  
Lanes labeled XIV contain DNA molecular weight marker XIV. 
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Samples from the degradation series as well as an untreated sample (0 min) were assayed in triplicate with 
the nuTH01-nuCSF-IPC triplex qPCR assay.  As expected, due to their quite dissimilar amplicon lengths, the 
nuTH01 and nuCSF portions of the assay experienced different sensitivities to the level of degradation in the 
DNase-treated samples (Figure 17, see below).  Just as the agarose gel showed a gradual progression in 
degree of degradation in the samples, so did the qPCR-based degradation ratios display a similarly gradual 
progression (Table 9, see below). 
The development of guidelines for the analysis of degraded samples required the testing of such 
samples under a variety of conditions.  With this in mind, AmpFlSTR® Identifiler
™ PCR amplifications were 
performed for each sample in the DNase degradation series using DNA concentrations determined by the 
nuTH01 portion of the assay.  (For the purpose of STR genotyping of degraded samples, we had previously 
determined that a large qPCR target sequence is more appropriate for DNA quantifications than is a short 
qPCR target (9).)  Where possible, 1, 2, and 4 ng of template were amplified for each degradation timepoint.  
These different quantities were used to test the hypothesis that higher genotyping success rates might be 
achievable by increasing the overall template amount (from the manufacturer recommended template amount 
of 1 ng to 2 and 4 ng) so that the longer STR target sequences, which are present in relatively smaller 
concentrations in degraded samples, might amplify to give stronger signals after electrophoretic resolution 
and detection.  For the three final timepoints the extremely low concentrations of DNA in these samples, 
coupled with the 10 µL maximum template input volume allowed in Identifiler™ reactions, made it possible 
to perform only 1 and 2 ng amplifications on the 60 min sample and 1 ng only on the 90 and 180 min 
samples.  PCR product from each amplification was electrokinetically injected on the ABI Prism® 3100 
Genetic Analyzer for 3, 5 and 10 seconds, in order to determine if any of the permutations of injection time 
and initial template quantity would lead to increased genotyping success rates for degraded samples.  Results 
are summarized in Table 9, from which several conclusions can be drawn: 
(a)  Across the set of DNase-degraded samples, an increase in the qPCR degradation ratio was 
correlated with an increase in interlocus imbalance in the STR profiles due to DNA degradation.  In Table  
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FIG. 17 - Amplification curves for DNase I degraded samples.  Although all samples were assayed in 
triplicate, for clarity only a single replicate is displayed for each.  Times indicate length of DNase treatment 
for each sample. 
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TABLE 9 - Summary of AmpFlSTR® Identifiler
™ STR results for DNase I degraded HL60 DNA.  Detected 
stutter peaks, incidences of incomplete non-template nucleotide addition (“-A peaks”) and off-scale peaks 
are indicated as “s”, “a” and “o”, respectively.   
 
   % Peaks Detected  D19/D18 STR Ratio 
Sample  Template  3 sec inj.  5 sec inj.  10 sec inj.  3 sec inj.  5 sec inj.  10 sec inj. 
qPCR 
Degradation 
Ratio 
0 min  1 ng  100  100  100  0.6  0.7  0.7  1.6 
       1s, 1a       
 2  ng 100  100  100  0.9  0.9  0.9   
   2s, 2a  2s, 2a  1s, 2a       
 4  ng 100  100  100  1.4  1.5  1.3   
   2s, 5a  2s, 5a  4s, 5a, 2o       
2.5 min  1 ng  100  100  100  1.1  1.2  1.2  1.5 
 2  ng 100  100  100  1.6  1.6  1.6   
     1s, 1a  1s, 3a       
 4  ng 100  100  100  2.5  2.4  2.4   
   1s, 4a  2s, 4a  3s, 4a, 1o       
5 min  1 ng  100  100  100  1.6  1.6  1.7  2.0 
 2  ng 100  100  100  2.4  2.3  2.3   
   1s, 1a  1s, 1a  2s, 3a, 1o       
 4  ng 100  100  100  3.6  3.5  2.5   
   2s, 6a  3s, 5a  4s, 5a, 2o       
10 min  1 ng  96  100  100  2.6  2.5  2.6  2.9 
 2  ng 92  100  100  4.1  4.1  3.9   
       1s, 3a, 1o       
 4  ng 100  100  100  6.4  6.2  3.5   
   3s, 7a  3s, 6a, 1o  5s, 7a, 3o       
15 min  1 ng  72  92  100  4.6  4.5  4.5  3.9 
 2  ng 92  92  100  8.2  7.9  6.1   
   1s, 1a  1s, 2a  2s, 4a, 1o       
 4  ng 92  92  100 10.3  10.4 6.1   
   1s, 7a  3s, 6a, 1o  5s, 7a, 2o       
20 min  1 ng  72  92  92  8.3  8.4  8.6  6.5 
      1o       
 2  ng 84  92  96  13.3  13.2 9.2   
   1s, 2a  1s, 4a  3s, 5a, 2o       
 4  ng 84  92  92  19.1  17.1 8.7   
   1s, 8a  2s, 8a, 2o  5s, 7a, 2o       
25 min  1 ng  72  88  92  11.6  11.9  11.1  5.5 
      1o       
 2  ng 68  84  92  35.0  19.6  14.5   
   2a  1s, 3a  1s, 4a, 2o       
 4  ng 80  84  92  27.4  26.4  13.3   
   7a  1s, 8a, 2o  4s, 7a, 2o       
40 min  1 ng  60  80  88  -  29.0  18.8  9.7 
   1a  1s, 1a  1s, 2a, 2o       
 2  ng 60  72  84  -  83.9  25.3   
   3a  6a, 1o  3s, 7a, 2o       
  4  ng  48 52 72 - - -   
   7a  8a, 2o  1s, 9a, 2o       
60  min  1  ng  48 72 80 - - - 28.1 
   3a  6a, 1o  2s, 7a, 2o       
  2  ng  28 28 36 - - -   
   4a 3a  5a,  1o       
90  min  1  ng  4  8  12 - - - 43.6 
180  min  1  ng  0  0  0 - - - 25.0 
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9, we represent the appearance of degradation in the STR profile by a single number, the ratio of the short 
(121 bp) D19 locus intensity to the long (average allele length 293 bp) D18 locus intensity, because we had 
previously found that this ratio was a simple STR-based metric for DNA degradation (9).  
(b)  For non-degraded and moderately degraded (2.5-10 min of DNase treatment) samples, 100% of 
the STR alleles were detected when using the nuTH01 qPCR quantification results in conjunction with our 
standard STR amplification (1 ng template) and electrophoresis (5 sec injection time) conditions.  For these 
particular samples, as expected, an increase in the template quantity and/or injection time generally led to 
less than optimal genotyping results.  For example, increasing the quantity of template generally increased 
the number of off-scale STR alleles, the number of alleles with shoulders due to incomplete non-template 
nucleotide addition (“-A peaks”) and the number of alleles with stutter peaks above the analytical detection 
threshold.  In addition, the use of increased template generally led to poorer interlocus balance, as reflected 
by increasing ratios of D19 to D18 STR signals.  Increasing the electrophoresis injection time often led to 
increases in the number of off-scale, -A, and stutter peaks detected above the analysis threshold, although the 
injection time had no detrimental effect on interlocus balance. 
  (c) For more highly degraded samples (15-60 min of DNase treatment), the standard amplification 
and electrophoresis conditions did not lead to 100% success rates for genotyping, primarily due to allelic 
dropout at the larger STR loci.  For these samples, moderate improvements in genotyping success rates could 
be obtained by increasing the injection time from 5 to 10 sec (e.g., an increased success rate of 80% to 88% 
of the alleles detected for the 40 min sample), although these improvements typically resulted in an increase 
in the number of STR artifacts (off-scale, stutter or -A) detected above threshold.  An increase in the amount 
of template to 2 or 4 ng, however, did not generally lead to any improvements in genotyping success rates.  
Instead, the main effect of increasing the quantity of template for these samples was to increase the number 
of artifact signals and to decrease the success rate for genotyping.  When using the Identifiler
™ amplification 
kit, these results indicate that the detrimental effects of DNA degradation on STR genotyping cannot be 
overcome simply by adding more template, but are better addressed by using the recommended 1 ng of 
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template DNA as determined by the longer-target assay, then judiciously increasing the injection time to 10 
seconds in order to detect some additional fraction of the larger alleles. 
(d)  For the most highly degraded samples (90-180 min of DNase treatment), very low genotyping 
success rates were seen.  For these samples, the nuTH01 qPCR quantifications were 8.3(SD=1.3) pg and 
5.9(4.4) pg per assay, respectively.  These values, which are well below the lowest point (32 pg) in the qPCR 
standard curve for our triplex assay, correspond to average CTs greater than 37 cycles and to a range that is 
below the accurate quantification limit for the assay.  It is likely that the low genotyping success rate seen for 
these highly degraded samples is simply due to limits in accuracy of the nuTH01 qPCR assay at these very 
low copy numbers.  It is possible that these very highly degraded samples would have benefited from 
increasing the STR amplification input to 2 or 4 ng, though we did not test for this possibility. 
 
Detection of PCR Inhibition with the nuTH01-nuCSF-IPC Triplex qPCR Assay  
The IPC was specifically included in the triplex degradation assay to detect for the presence of PCR 
inhibition.  To assess the sensitivity of the IPC to inhibition, a series of artificially inhibited DNA extracts 
were examined using the triplex qPCR assay.  Twenty identical tubes of non-degraded DNA were treated 
with different amounts of hematin, a known PCR inhibitor (78), such that the final concentrations of hematin 
in the standard 20 µL qPCR assays ranged from 0 µM to 160 µM.  Each sample was assayed in duplicate 
with the nuTH01-nuCSF-IPC triplex qPCR assay, and the results are summarized in Table 10.  It is evident 
from these results that an increased concentration of hematin can lead to one or more changes in the qPCR 
signal, including: (i) the complete loss of an amplification curve (a “null” amplification); (ii) a delayed CT; 
and/or (iii) a reduced final fluorescence signal (lower ∆Rn).   
To determine how results from the IPC assay are predictive of success in STR genotyping, samples 
from the hematin-inhibition series were amplified and genotyped using the AmpFlSTR® Identifiler
™ kit.  
For these amplifications, 1 ng quantities of template DNA were used based on estimates by both the nuTH01 
and nuCSF qPCR assays.  If, based on the qPCR assays, the use of 1 ng of template was not possible, 10 µL 
of extract was used.  The STR results are summarized in Table 10, which includes a comparison of the 
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TABLE 10 - Summary of nuTH01-nuCSF-IPC triplex qPCR and AmpFlSTR® Identifiler
™ STR results using TaqMan® Control Human Genomic 
DNA inhibited to varying degrees with hematin. Percentages of STR peaks detected are percentages obtained with 5 second injections only. 
 
  nuTH01-nuCSF-IPC qPCR Results  Identifiler™ STR Results 
IPC Assay: Using Input Quantity from: nuTH01 Assay Using Input Quantity from: nuCSF Assay µM Hematin in 
qPCR Assay Mean (StDev) CT Mean (StDev) ∆Rn Ratio µM Hematin in STR Amp % Peaks Detected µM Hematin in STR Amp % Peaks Detected
0 µM + NaOH  27.57 (1.03)  0.88 (0.161)  0  100  0  100 
0 µM  27.43 (0.40)  0.93 (0.153)  0  100  0  100 
5 µM  27.91 (0.16)  0.77 (0.135)  2  100  2  100 
10 µM  27.74 (0.15)  0.96 (0.159)  3  100  4  100 
15 µM  28.32 (0.38)  0.86 (0.141)  5  100  5  100 
20 µM  28.42 (0.08)  0.69 (0.114)  7  100  9  100 
25 µM  28.52 (0.18)  0.71 (0.131)  9  100  11  100 
30 µM  28.05 (0.42)  0.69 (0.113)  13  100  15  100 
35 µM  27.76 (0.48)  0.61 (0.113)  13  100  19  100 
40 µM  28.03 (0.04)  0.54 (0.098)  26  61  36  0 
45 µM  30.21 (0.02)  0.36 (0.061)  36  7  40  0 
50 µM  30.65 (0.53)  0.36 (0.091)  61  0  45  0 
55 µM  30.67 (0.26)  0.32 (0.069)  110  0  70  0 
60 µM  31.35 (0.07)  0.29 (0.053)  120  0  112  0 
65 µM  30.92 (0.56)  0.27 (0.079)  130  0  130  0 
70 µM  31.28 (0.43)  0.41 (0.071)  140  0  140  0 
75 µM  31.78 (2.18)  0.44 (0.144)  150  0  150  0 
80 µM  31.20 (0.21)  0.48 (0.081)  160  0  160  0 
120 µM  41.93 (*)  0.13 (0.060)  240  0  240  0 
160 µM  -  -  320  0  320  0 
    * Only one replicate was detected above the analysis threshold. 
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genotyping success rate to the final hematin concentration in each Identifiler
™ STR amplification.  
Depending on which quantitation assay was used, this comparison indicates that the STR amplification 
became partially inhibited at concentrations of 26-36 µM  hematin and were completely inhibited starting at 
36-61 µM.   The IPC assay began to show an inhibition effect, as evidenced by a delay in the CT value, at 45 
µM and above that concentration continued to exhibit progressively greater delays in CT (Table 10).  There 
was, in addition, one aspect of the IPC portion of the triplex assay that correlated to reduced success rates for 
STR genotyping - that aspect was the hematin-induced reduction in the final ∆Rn value.  These reductions in 
∆Rn for the IPC assay are represented in Table 10 as the “∆Rn ratio,” which were calculated as the ratio of the 
final ∆Rn for the sample to the average final ∆Rn for the non-inhibited control samples.  Based on these 
results, our current interpretation guidelines for using the IPC to positively indicate for inhibition are: (i) total 
absence of an IPC amplification curve; (ii) a CT delay of ≥1 in the IPC relative to the mean CT of the non-
inhibited control samples used in that run; (iii) a ∆Rn ratio in the IPC that is ≤60%.  The last indicator is the 
most sensitive for predicting inhibition using our IPC system.   
 
Casework-type Samples with the nuTH01-nuCSF-IPC Triplex qPCR Assay  
Twenty-three non-probative and simulated casework samples were quantified to assess the capability 
of the nuTH01-nuCSF-IPC triplex qPCR assay to accurately quantify DNA in forensic samples.  It was also 
desirable to determine if evidence of DNA degradation in these samples, as detected by the qPCR assay, 
would be predictive of STR genotyping success.  Each sample was amplified twice with the AmpFlSTR® 
Identifiler
™ PCR Amplification kit, once using 1 ng of template DNA based on qPCR quantification of a 
long target sequence (nuTH01) and a second time using 1 ng of template based on a short target (nuCSF).  
The purpose of the two amplifications was to confirm that for highly degraded DNA samples optimal STR 
genotyping success rates would be achievable using quantifications based on the longer qPCR assay (9).  
PCR product from each amplification was injected for 5 sec on the ABI Prism® 3100 Genetic Analyzer.   
Results from this study are summarized in Table 11.  Based on the STR genotyping success rate (“% 
Peaks Detected”), it is clear that the nuTH01 portion of the triplex qPCR assay provided accurate  
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TABLE 11 - Summary of nuTH01-nuCSF-IPC qPCR quantification and AmpFlSTR® Identifiler
™ STR 
results for selected casework-type samples.  All quantification results are from single replicate experiments.  
Average peak height is the total RFU signal from detected peaks at all loci divided by the total number of 
detected peaks. 
  
% Peaks Detected  D19/D18 Ratio 
Average Peak 
Height (RFU) 
 
Sample 
 
Sample Type 
 
qPCR 
Degradation 
Ratio  nuTH01 
Assay 
nuCSF 
Assay 
nuTH01 
Assay 
nuCSF 
Assay 
nuTH01 
Assay 
nuCSF 
Assay 
1 Blood  13.9  93  52  22.8  -  1319  122 
2 Tooth  1.3  100  100  1.7  1.6  714  630 
3 Blood  0.7  100  100  1.1  1.0  591  1039 
4 Muscle  0.8  100  100  1.3  1.7  695  759 
5 Toothbrush  1.3  100  100  1.7  1.3  785  666 
6 Toothbrush  1.1  100  100  1.3  1.6  798  642 
7 Razor  Shavings  3.1  100  97  5.7 3.4 821  321 
8 Toenails  2.6 97  89  9.8  5.8  828  343 
9 Toenails  3.4 100  89  5.3  4.0  829  290 
10 Femur  4.0  100  70  9.2  9.5  887  304 
11 Blood  on  Redwood  1.1  100  100  1.3  1.2  998  1089 
12  Blood in Soil  2.3  100  100  2.9  1.4  1478  480 
13 Cigarette  Butt  1.8  100  100 2.6 1.8  1022 503 
14 Blood  on  Denim  1.2  100  100  2.4  2.1  984  1101 
15 Semen  on  Wool  1.2  100  100  1.2  1.1  792  619 
16  Semen on Cotton  1.0  100  100  1.2  1.7  1054  965 
17  Semen  on  Wool  2.1  100  100 1.8 1.3  1312 619 
18  Semen on Cotton  1.4  100  100  1.6  1.2  1105  615 
19  Semen on Boxers  3.4  100  91  8.8  5.3  1045  371 
20 Buccal  Swab  1.8  100 100 2.6 2.3 911  437 
21 Buccal  Swab  2.0  100 100 2.1 2.4 644  312 
22 Buccal  Swab  1.3  100 100 1.2 1.0 664 1021 
23 Control  DNA  1.1  100  100 0.6 0.5 379 384 
 
 
quantifications.  Only two samples (1 and 8) yielded less than 100% genotyping success rates.  These were 
the two most degraded samples based on the D19/D18 STR intensity ratios.  There was also generally good 
concordance between the values of the qPCR-based degradation ratio and the D19/D18 STR intensity ratio.  
Based solely on this small set of casework-type samples, it appeared that when a degradation ratio was 
measured to be greater than ~2.5, then some degree of interlocus imbalance (D19/D18 > ~5) in the STR 
profile could be predicted.  There were no amplification artifacts except in sample 1 which contained three 
stutter peaks, four -A peaks and one off-scale peak.  For the entire set of samples, there were neither strong 
signs of inhibition indicated by the IPC portion of the triplex qPCR assay nor evidence of PCR inhibition 
suggested by the STR results.  When quantifications from the short nuCSF qPCR assay were used to prepare 
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“1 ng” of template DNA for STR amplification, decreased genotyping success rates were observed for 
degraded samples (samples 1, 7-10, and 19).  Due to the short qPCR target sequence, the nuCSF assay 
overestimated the quantity of amplifiable DNA.  As a consequence, larger STR alleles were undetected and 
lower than optimal average STR peak heights were obtained. 
 
Conclusions 
We have previously described the importance of qPCR target sequence length when quantifying 
DNA for STR genotyping (9).  Results using the nuTH01-nuCSF-IPC triplex assay confirm that, for highly 
degraded samples, improved genotyping success rates are obtained when an appropriately long qPCR target 
(the nuTH01 target) is used for determining the amount of template to be amplified for STR analysis. 
We have also shown that a degradation ratio, calculated from quantitation results obtained with the 
nuTH01-nuCSF-IPC triplex qPCR assay, provides a good estimate of the quality of extracted DNA.  In the 
past, information about DNA quality has been difficult to obtain and was not quantitative.  Typically, the 
extent of DNA degradation could be assessed only by gel electrophoresis with ethidium bromide staining, a 
procedure that is laborious, not very sensitive and could consume much of a sometimes precious sample. If 
the sample quantity was very limited, generally no information about DNA quality could be obtained, 
leaving the analyst to make an educated guess based on the condition of the tissue from which it was 
extracted.  As described here, the nuTH01-nuCSF-IPC triplex qPCR assay is a tool for simultaneously 
assessing the quantity and quality of DNA thereby sacrificing a minimal quantity of extract.  Furthermore, 
the inclusion of an internal PCR control provides immediate feedback about the amplification “status” of the 
sample.  If the IPC does not successfully amplify, steps can be taken to overcome PCR inhibition before STR 
genotyping is attempted.  Given that the primary sample-related variables directly impacting the success of 
STR genotyping are quantity of DNA, quality of DNA, and purity of the DNA sample with regard to PCR 
inhibitors, and given that forensic samples often tend to be compromised in one or more of these regards, the 
triplex qPCR assay described here should be a valuable tool that will improve the first-pass success rate for 
STR genotyping, thus minimizing the consumption of extracted DNA and maximizing the throughput and 
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efficiency of DNA analysis. Finally, the nuTH01-nuCSF-IPC triplex assay should be useful for identifying 
those samples that would be analyzed more successfully with newly developed genotyping technologies 
(e.g., mini-STRs (79,80) or SNP genotyping (81)), rather than with the STR technologies currently in 
common use. 
  
(iii) Design and Development of a Human Y-Chromosome-Specific qPCR Assay 
 
Introduction 
  The development of a qPCR assay specific for the human Y-chromosome was motivated primarily 
by its potential utility for the analysis of sexual assault casework samples.  Such an assay would allow the 
analyst to differentiate those samples that contain sufficient male DNA for genotyping from those that 
contain so little male DNA that further analyses, at least by the STR methods currently in common use, 
would be uninformative.  Moreover, the combined quantitation information from a Y-specific qPCR assay 
and an autosome-specific qPCR assay could provide an estimate of the relative amounts of human male and 
female DNA in an extract.  This information could then be used to differentiate those samples that would 
benefit from “standard” autosomal STR genotyping approaches (i.e., those samples with 
maleDNA:femaleDNA ratios greater than ~1:10) from those samples that would be analyzed more 
productively using Y-specific amplification methods (e.g., using Y-STRs (82)). 
  Given the potential utility of such an assay, it is not surprising that several Y-specific qPCR assays 
have been previously described, both for forensic (33,38,83-84) and clinical (85) applications, including a 
commercially available Y-chromosome-specific forensic assay (30).  Our primary interest was in developing 
a Y-specific assay that would be not only useful in singleplex but that could be multiplexed with an 
autosomal qPCR assay in order to save DNA extract and to increase the efficiency of analysis.  To this end, 
we designed and tested a number of singleplex Y-chromosome-specific qPCR assays, some of the more 
promising of which will be described here.  Developmental work on the Y-autosome multiplex qPCR assay 
is preliminary and ongoing. 
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Methods and Materials 
Pre-quantified, high molecular weight human genomic male DNA (#G1471), purchased from 
Promega (Madison, WI), was used as a quantification standard and positive control for the Y-specific assays.  
Pre-quantified, high molecular weight human genomic female DNA (#G1521), also from Promega, was used 
as a negative control for gender specificity. 
Real-time qPCR assays were designed as described previously (9) using PrimerExpress
TM(v2.0) 
software defaulted to the Applied Biosystems Universal TaqMan
TM assay conditions.  Based on a previously 
reported Y-chromosome-specific qPCR assay for clinical applications (85), design work centered on an 
intronic region (Yp11.3) of the SRY gene, in particular using bases 1726-1965 from GenBank locus L10102 
(HUMSRYB).  Some efforts were also made to design assays at or near published Y-STR loci (82).  These 
design efforts were unsuccessful (results not shown), mainly because sequences between the primers and the 
Y-STRs were not suitable (too short, or too AT-rich) for placement of a TaqMan
TM detection probe.  Prior to 
ordering synthetic oligonucleotides for experimental work, potential primer and probe sequences were 
compared to DNA sequences available through the NCBI website by using the Basic Local Alignment 
Search Tool (BLASTn) (50).  The purpose of these comparisons was to identify and avoid inadvertent 
homologies of primers and/or probes to non-target genomes that might lead to undesirable cross-species or 
cross-chromosome reactivities.  Primer and probe sequences for selected Y-specific qPCR assays are 
provided in Table 12.  The primers labeled “MT1SRYF” and “MT1SRYR” had been used previously for a 
clinical assay (85).  Otherwise, the primers and probes were designed as outlined above.  The 
oligonucleotides listed in Table 12 were used in various combinations to construct potential Y-specific qPCR 
assays, as indicated by the assays listed in Table 13. 
All qPCR assays were run in singleplex, using either SYBR
TM Green or TaqMan
TM detection.   
Assays using SYBR
TM Green detection chemistry were run as 20 µL amplifications that included 10 µL of 
SYBR
TM Green Master Mix 2X, no UNG (Applied Biosystems), 4 µL of sample, with the remaining 6 µL 
composed to give final concentrations of 0.16 µg/µL non-acetylated BSA (Sigma) and 300 nM in each 
primer.  Assays using TaqMan® detection chemistry were run as 20 µL amplifications that included 10 µL of 
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TABLE 12 - Primer and probe sequences used for selected Y-chromosome-specific qPCR assays. Oligonucleotides were obtained from Operon 
(Alameda, CA), unless otherwise indicated (from ABI). 
____________________________________________________________________________ 
 
Oligonucleotide    Sequence  (5’  → 3’) 
____________________________________________________________________________ 
 
SRYNEWF1      CGC ATT TTT CAG GAC AGC AGT A 
SRYNEWF2      CGT TTT GTG ACA TAA AAG GTC AAT G 
SRYNEWR1      AAA CAT GGT AAT TCA GTA ACG TTG ACT AC 
MT1SRYF      TGG CGA TTA AGT CAA ATT CGC 
MT1SRYR      CCC CCT AGT ACC CTG ACA ATG TAT T 
SRYMODF1      AAA TTG GCG ATT AAG TCA AAT TCG 
SRYMODR2      GTA TTC ATT CTC AAG CAA AAC ATG GTA A 
SRYNEWTM1       HEX-TGC CCT GCT GAT CTG CCT CCC T-BHQ 
YTMMGB1       VIC-CCC TGC TGA TCT GCC T-MGBNFQ (ABI) 
VICSRYaMGB1     VIC-ATT CTC AAG CAA AAC ATG-MGBNFQ (ABI) 
_______________________________________________________________ 
 
 
TABLE 13 - Descriptions of and results for selected Y-chromosome-specific qPCR assays.  Results are shown for the TaqMan
TM- (or 
TaqManMGB
TM-)detected assays only.  Sequence information for the primers and probes is provided in Table 12. 
 
  Oligonucleotides Used in Assay  Sequence Parameters  Assay Fluorescence Signal Strength  Parameters Derived 
from Assay Standard Curve 
Standard Deviation of CT 
at Various DNA Inputs 
Assay        F.Primer R.Primer Probe
Length of 
Amplicon 
(bp) 
Length of 
Probe 
(nt) 
3’ Primer to 
5’ Probe 
(nt) 
Probe Signal 
Before Hydrolysis
(RFU) 
Probe Signal 
After Hydrolysis 
(RFU) 
Final     
Delta Rn 
Value 
PCR 
Efficiency 
(%) 
Y-Intercept 
(cycle)  R-Squared 
at 
6.4ng
(cycle)
 at 
0.64ng
(cycle)
at 
0.064ng 
(cycle) 
SRY-1 SRYNEWF2 SRYNEWR1  SRYNEWTM1  131  22  2  1200  2850  1.2  92.4  32.4  0.979  0.16  0.15  0.55 
SRY-2 SRYNEWF1 SRYNEWR1  YTMMGB1  82  16  4  850  4000  2.1  79.0  32.0  0.956  1.12  0.02  0.73 
SRY-3 SRYNEWF2 SRYNEWR1  YTMMGB1  131  16  4  800  4250  2.8  95.0  31.6  0.988  0.13  0.18  0.44 
SRY-4                           
                               
MT1SRYF MT1SRYR VICSRYaMBG1 137 18 2 1450 3900 1.6 90.7 32.7 0.971 0.30  0.15  0.74
SRY-5 MT1SRYF MT1SRYR YTMMGB1 137 16 45 800 4400 2.7 91.2 30.7 0.992 0.19 0.08 0.35
SRY-6 SRYMODF1 SRYMODR2  YTMMGB1  121  16  22  800  4100  2.3  97.2  31.1  0.993  0.02  0.42  0.12 
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TaqMan® Universal Master Mix 2X, no UNG (Applied Biosystems), 4 µL of sample, with the remaining 6 
µL composed to give final concentrations of: 0.16 µg/µL non-acetylated BSA (Sigma), 600 nM in each 
primer, and 200 nM in TaqMan
TM (or TaqManMGB
TM) probe. 
Real-time qPCR data were collected on an Applied Biosystems Prism® 7000 SDS instrument 
controlled by version 1.0 or 1.1 of the 7000 SDS Collection software.  The instrument was 
typicallyconfigured for the following run conditions: 20 µL sample volumes; 9600 emulation mode; one 10 
minute 95 ºC polymerase activation step, followed by 45 cycles of 2-step qPCR (15 s of 95 ºC denaturation, 
60 s of 60 ºC combined anneal/extension).  Well-to-well variations in background fluorescence were 
corrected for by use of a ROX-labeled passive reference oligonucleotide, included as part of the Applied 
Biosystems qPCR Master Mix for each sample.  For runs that used SYBR® Green detection, a melt curve 
was collected after the final cycle of PCR extension by configuring the SDS Collection software to monitor 
SYBR® Green fluorescence as the temperature was increased (~1.8 ºC /min) from 60 ºC to 95 ºC.  
Amplification curves were analyzed by using empirically established threshold and baseline settings.  For 
assays that used SYBR® Green detection, the threshold was set at 0.15; for assays that used TaqMan
TM (or 
TaqManMGB
TM) detection, the threshold was set from 0.08 to 0.1, with the goal of keeping the threshold in 
the middle of the exponential growth portion of the amplification curves for each type of assay.  For both 
types of detection, data from cycles 6 through 15 were used for baseline corrections. 
For each qPCR run, the SDS Collection software generated a linear standard curve plot of CT (cycle 
threshold) vs. log C0 (initial standard DNA concentration) by using amplification results from a freshly 
prepared dilution series of pre-quantified high molecular weight human genomic standard DNA (male).  
Standard curves were constructed using data from standard DNA dilutions containing 6.4 ng (or 3.2 ng) of 
total DNA per sample (in duplicate), 0.64 ng (in triplicate) and 0.064 ng (in replicates of five).  For negative 
controls, TE
-4 (in duplicate), 0.32 ng female DNA (in duplicate), and 64 ng female DNA (in duplicate) were 
included for each assay.  Nuclear DNA copy numbers were estimated using the ratio of one haploid 
autosomal copy per 3.3 pg genomic DNA or one copy of Y chromosome per 6.6 pg genomic DNA (55).  
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Where appropriate, qPCR amplification efficiencies were determined from the slopes of the linear calibration 
curves (% PCR efficiency = 100[(10
(-1/slope) - 1)]) (56). 
 
Results 
  In developing a Y-chromosome-specific assay, we considered several important qPCR properties: (i) 
specificity for amplifying the Y-chromosome (i.e., no spurious cross-reactivity to human autosomes or to the 
X-chromosome); (ii) absence of amplicon in no-template control samples (TE
-4); (iii) PCR efficiency 
(>90%); (iv) fluorescence signal strength; (v) quality of standard curve (correlation coefficient); (vi) 
sensitivity of quantification; and (vii) precision of quantification (e.g., standard deviation of CT), especially at 
low copies of template.  A number of potential Y-specific qPCR assays were examined, and six promising 
TaqMan®-detected assays were identified based on the criteria just listed.  Results using these assays are 
provided in Figure 18 (SYBR® Green-detected) and in Table 13 (TaqMan®-detected). 
  As indicated by the SYBR® Green-detected results shown in Figure 18, most primer combinations 
showed no evidence for any spurious amplification of either female DNA or TE
-4.  The primers for assays 
SRY-1 and SRY-3 showed a very slight amplification of female DNA (Fig. 18(b)) in one of two replicates, 
though the lateness of CT (41 cycles, corresponding to a deduced template amount of 0.17 pg) indicated that 
the spurious amplification was very inefficient.  Neither assay SRY-1 or SRY-3 showed any amplification of 
female DNA when using TaqMan® detection (results not shown). 
  Table 13 summarizes the pertinent properties of the six TaqMan®-detected Y-specific assays.  Based 
upon these properties, assays SRY-5, SRY-3, and SRY-6 appear to be the most promising candidates for 
further work.  Assays SRY-1 and SRY-4 showed relatively poor final fluorescence signals (final delta Rn 
values less than 2), and assay SRY-2 exhibited relatively poor PCR efficiency (<80%) and poor CT precision.  
Moreover, SRY-2 amplifies a short target sequence (82 bp), which may not be ideal for quantifying DNA in 
degraded samples. 
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FIG. 18 - SYBR
TM Green qPCR results for selected Y-chromosome-specific qPCR assays.  For each assay, 
the top panel shows amplification curves from a standard dilution series of male DNA; the bottom panel 
shows the corresponding melt (or dissociation) curves.  Panel (a) provides the template quantities used for 
each standard dilution series. 
 
 
(a) SRY-4 and SRY-5 (forward primer = MT1SRYF, reverse primer = MT1SRYR) 
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(b) SRY-1 and SRY-3 (forward primer = SRYNEWF2, reverse primer = SRYNEWR1) 
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(c) SRY-2 (forward primer = SRYNEWF1, reverse primer = SRYNEWR1) 
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(d) SRY-6 (forward primer = SRYMODF1, reverse primer = SRYMODR2) 
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Discussion 
  Having identified at least three promising Y-chromosome-specific qPCR assays, the next steps will 
be to examine their abilities to provide accurate quantifications under less than ideal conditions, in particular, 
in mixtures with large excesses of human female DNA and in mixtures with excesses of non-human 
(microbial and non-microbial) DNAs.  The assays will also be examined in duplex with autosomal qPCR 
assays and with an IPC assay.  This work is ongoing. 
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